#### "COMPARISON OF SPINAL ANAESTHESIA WITH HYPERBARIC LEVOBUPIVACAINE WITH FENTANYL AND HYPERBARIC BUPIVACAINE WITH FENTANYL IN ELECTIVE CESAREAN SECTIONS"

#### B.L.D.E.(DU), SHRI B.M. PATIL MEDICAL COLLEGE HOSPITAL & RESEARCH CENTRE, VIJAYAPUR, KARNATAKA, INDIA



In partial fulfilment of the requirements for the degree of

#### DOCTOR OF MEDICINE IN ANAESTHESIOLOGY

BY Dr. SINCHANA. A. S M.B.B.S

POST GRADUATE IN ANAESTHESIOLOGY 2024

Under the guidance of DR. VIJAYKUMAR T.K MD PROFESSOR DEPARTMENT OF ANAESTHESIOLOGY

DOI 10.5281/zenodo.15501608 https://zenodo.org/records/15501609

[1]

#### BLDE(DU) VIJAYAPUR, KARNATAKA

#### **DECLARATION BY THE CANDIDATE**

I hereby declare that this dissertation entitled "COMPARISON OF SPINAL ANAESTHESIA WITH HYPERBARIC LEVOBUPIVACAINE WITH FENTANYL AND HYPERBARIC BUPIVACAINE WITH FENTANYL IN ELECTIVE CESAREAN SECTIONS" is a bonafide work carried out by me under the direct supervision and guidance of DR. VIJAYKUMAR T.K. M.D, Professor, Department of Anesthesiology Shri B.M. PATIL Medical college, Vijayapura.

Linchas

Dr. SINCHANA. A. S

Date:

Place: Vijayapura

#### BLDE (DU) VIJAYAPUR, KARNATAKA

#### **CERTIFICATE BY THE GUIDE**

This is to certify that the dissertation entitled "COMPARISON OF SPINAL ANAESTHESIA WITH HYPERBARIC LEVOBUPIVACAINE WITH FENTANYL AND HYPERBARIC BUPIVACAINE WITH FENTANYL IN ELECTIVE CESAREAN SECTIONS" is a bonafied work done by Dr. SINCHANA. A. S. under my direct supervision and guidance in partial fulfillment of the requirement for the degree of M.D. (Anaesthesiology).

Date: Place: Vijayapura Rohpupper

DR. VIJAYKUMAR T.K MD PROFESSOR DEPARTMENT OF ANAESTHESIOLOGY

#### **BLDE (DU) VIJAYAPUR, KARNATAKA**

#### **ENDORSEMENT BY THE HOD**

#### This is to certify that the dissertation entitled "COMPARISON OF SPINAL ANAESTHESIA WITH HYPERBARIC LEVOBUPIVACAINE WITH FENTANYL AND HYPERBARIC BUPIVACAINE WITH FENTANYL IN ELECTIVE CESAREAN SECTIONS" is a bonafied work done by Dr. SINCHANA. A. S under the direct supervision and guidance of DR. VIJAYKUMAR T.K M.D., Professor, Department of Anaesthesiology, Shri B. M. PATIL Medical college, Vijayapura.

Alli

Dr. RENUKA HOLYACHI MD

Professor and HOD Department of Anesthesiology Shri B.M. Patil Medical College Vijayapura.

Date: Place: Vijayapura

#### **ENDORSEMENT BY PRINCIPAL**

#### This is to certify that the dissertation entitled "COMPARISON OF SPINAL ANAESTHESIA WITH HYPERBARIC LEVOBUPIVACAINE WITH FENTANYL AND HYPERBARIC BUPIVACAINE WITH FENTANYL IN ELECTIVE CESAREAN SECTIONS" is a bonafied work done by Dr. SINCHANA. A. S under the direct supervision and guidance of DR. VIJAYKUMAR T.K M.D., Professor, Department of Anaesthesiology, Shri B. M. Patil Medical college, Vijayapura.

Date: Place: Vijayapura Holy.

Dr. ARAVIND PATIL<sub>MD</sub> Principal

Shri B.M. Patil Medical College Vijayapura.

#### COPYRIGHT

#### **DECLARATION BY THE CANDIDATE**

I hereby declare that B.L.D.E. (DU) Shri B. M. Patil Medical College, Vijayapura shall have the rights to preserve, use and disseminate this dissertation in print or electronic format for academic / research purpose.

Lincha Dr. SINCHANA. A. S

Date: Place: Vijayapura

© B.L.D.E. (DU) Shri B.M. Patil Medical College, Vijayapura.

#### ACKNOWLEDGEMENT

On completion of my post-graduation journey and this scientific document, I would like to acknowledge the immense help received from my mentors in the department of Anaesthesiology. With privilege and respect, I would like to express my gratitude and indebtedness to my Guide, Dr. Vijaykumar T.K Professor, Department of Anaesthesiology and for his constant inspiration, extensive encouragement and loving support, which rendered in pursuit of my post-graduate studies and in preparing this dissertation.

I am forever grateful to Dr. RENUKA HOLYACHI, Professor and HOD of Department of Anaesthesiology, Shri B.M Patil Medical College, Hospital and Research Center, Vijayapura for her valuable suggestions, support and encouragement throughout the post graduate programme.

I am grateful to all my teachers in Department of Anesthesiology for their guidance, encouragement and inspiration.

I am extremely thankful to Professor Dr. Arvind Patil, Principal, of B.L.D.E.(DU) Shri. B.M. Patil Medical College, Hospital and Research Centre, Vijayapura, for permitting me to utilize resources in completion of my work.

My thanks to one and all staff of Library, Anaesthesia Department and Hospital for their co-operation in my study I am thankful to the members of ethical committee BLDEU 's Shri. B. M. Patil Medical College Hospital and Research Centre Vijayapura for permitting me to carry out this study.

I am thankful to Dr Vijaya for her help in statistical analysis. I also like to thank all my seniors and juniors for their help and co-operation.

I would like to express my deep-felt gratitude to my parents and to my husband for their constant support and encouragement throughout.

Last but not the least; I convey my heartfelt gratitude to all my patients, without whose co-operation, this study would be incomplete.

#### Dr. SINCHANA. A. S

#### TABLE OF CONTENTS

S.NO	TOPIC	P.NO
01.	INTRODUCTION	8-9
02.	AIM AND OBJECTIVES OF THE STUDY	10-11
03.	REVIEW OF LITERATURE	12-16
04.	TOPICS SPECIFIC TO STUDY	17-48
05.	MATERIALS AND METHOD	48-54
06.	RESULTS	55-70
07.	DISCUSSION	71-73
08.	SUMMARY	74
09.	CONCLUSION	75
10.	BIBILOGRAPHY	76-83
11.	ANNEXURE	
	I: ETHICAL COMMITTEE APPROVAL LETTER	84
	II: PLAGIARISM CERTIFICATE SCREEN SHOT	85
	III: PATIENT CONSENT FORM	86-91
	IV: PROFORMA	92-93
	V: BIODATA OF GUIDES AND INVESTIGATOR	94
	VI: MASTERCHART	95-98

# LIST OF FIGURES

SI. NO	FIGURE NAMES	Page No.
1	Number of spinal nerves	18
2	Ligaments in vertebral column	19
3	Anatomy of spinal cord	20
4	Blood supply of spinal cord	21
5	Common tip design for spinal needles	28
6	Lateral decubitus with universal flexion	30
7	Sitting position for spinal anaesthesia	31
8	Prone position for spinal anaesthesia	32
9	Pain pathway	37
10	Local anesthetic mechanism of action	39
11	Chemical structure of bupivacaine	40
12	Chemical structure of levobupivacaine	45
13	Visual analogue scale	54

# LIST OF TABLES

SI NO.	Table name	Page no.
1	Comparison of age distribution	56
2	Comparison of onset of sensory block	57
3	Comparison of time to reach T10 in minutes	58
4	Comparison of time to reach T4 in minutes	59
5	Comparison of regression of dermatome	60
6	Comparison of total duration of sensory block	61
7	Comparison of onset of motor block	62
8	Comparison about time to reach maximum level in minutes	63
9	Comparison of duration of analgesia	64
10	Comparison of episodes of hypotension	65
11	Comparison of episodes of bradycardia	66
12	Comparison of episodes of nausea and vomiting	67
13	Comparison of episodes of headache	68
14	Comparison of episodes of itching	69
15	Comparison of shivering	70

# LIST OF GRAPHS

SI NO.	Table name	Page no.
1	Comparison of age distribution	56
2	Comparison of onset of sensory block	57
3	Comparison of time to reach T10 in minutes	58
4	Comparison of time to reach T4 in minutes	59
5	Comparison of regression of dermatome	60
6	Comparison of total duration of sensory block	61
7	Comparison of onset of motor block	62
8	Comparison about time to reach maximum level in minutes	63
9	Comparison of duration of analgesia	64
10	Comparison of episodes of hypotension	65
11	Comparison of episodes of bradycardia	66
12	Comparison of episodes of nausea and vomiting	67
13	Comparison of episodes of headache	68
14	Comparison of episodes of itching	69
15	Comparison of shivering	70

# ABBREVIATIONS

- ASA- American society of anaesthesiologists
- CSF- Cerebrospinal fluid
- IV- Intravenous
- PDPH- Post dural puncture headache
- OT- Operation theatre
- LA- Local anaesthetics
- CNS- Central nervous system
- CVS- Cardiovascular system
- SD- Standard deviation
- ECG- Electrocardiogram
- mcg- Microgram
- Spo2- Percentage saturation of oxygen
- SBP- Systolic blood pressure
- DBP- Diastolic blood pressure

### ABSTRACT

#### **Background:**

Racemic hyperbaric bupivacaine is the most commonly used local anesthetic for spinal anesthesia in women undergoing elective cesarean section. Many studies have been conducted to attain the same level of blockade with different drugs and dosages which offer less adverse effects. The introduction of hyperbaric levobupivacaine, the pure S (–) enantiomer of bupivacaine, has become more prevalent in India due to its lower risks of cardiotoxicity and neurotoxicity, as well as a shorter duration of motor block. In order to increase the analgesic duration without motor block additives are added in elective cesarean delivery.

Nonetheless, there is limited research on its effectiveness in obstetric anesthesia. Therefore, this study aimed to compare the sensory and motor block levels and side effects of equal doses of hyperbaric bupivacaine and levobupivacaine with the addition of intrathecal fentanyl in elective cesarean deliveries.

#### **Materials and Methods:**

Following the approval of the College Ethical Committee, 30 parturients with ASA class I-II undergoing elective cesarean sections were enrolled in the study after providing informed consent. They were randomly assigned to either Group BF, receiving 10 mg (2 ml) hyperbaric bupivacaine and 25 mcg (0.5 ml) fentanyl, or Group LF, receiving 10 mg (2 ml) isobaric levobupivacaine and 25 mcg (0.5 ml) fentanyl. Sensory and motor block characteristics were evaluated using pinprick, cold swab, and the Bromage scale; hemodynamic changes and side effects were also recorded. Neonatal outcomes were assessed with the APGAR score at 1 and 5 minutes.

#### **Results:**

Hemodynamic parameters like mean arterial pressure of Group BF were found to be lower. Group BF exhibited maximum motor block level with longer duration of analgesia. Whereas, in Group LF, shorter sensorial and motor block scores were seen with lesser side effects. Hemodynamic stability is similar in both the groups with no effects on neonate.

#### **Conclusion:**

The combination of intrathecal hyperbaric levobupivacaine and fentanyl is a viable alternative to the hyperbaric bupivacaine-fentanyl combination in cesarean surgeries, as it is less effective in producing motor block while maintaining hemodynamic stability at higher sensory block levels.

**Key words**: Cesarean sections, hyperbaric bupivacaine, hyperbaric levobupivacaine, fentanyl.

# INTRODUCTION

#### **INTRODUCTION:**

Administering local anesthetics via the spinal route is favored for cesarean sections as it provides analgesia, anesthesia, and motor block. The effects are influenced by the volume, concentration, and dosage of the drug<sup>1</sup>. Racemic bupivacaine is the most frequently utilized local anesthetic for spinal anesthesia in women undergoing cesarean sections.

Hyperbaric solutions tend to produce cephalad spread which causes cardiothoracic fibers block leading to sudden bradycardia and arrest. They can also cause hemodynamic instability and bradycardia. Bupivacaine has a few adverse effects like cardiotoxicity and neurotoxicity. Levobupivacaine is the pure S enantiomer of bupivacaine and can be used in place of bupivacaine due to its lower cardiotoxicity and neurotoxicity. It also provides extended advantages because of its predictable spread after spinal anesthesia.

Incorporating low doses of opioids with local anesthetics during spinal anesthesia reduces the side effects associated with local anesthetics and prolongs their duration of action. It provides intra op and post op analgesia. Fentanyl can be added as it increases the duration of action and also spread of sensory blocks<sup>2</sup>. It also helps by reducing the dose of local anesthetic, thus reducing its side effects.

Therefore, the purpose of this study is to evaluate the sensory and motor block levels, along with the side effects resulting from equal doses of hyperbaric solutions of bupivacaine and levobupivacaine, when combined with intrathecal fentanyl, in elective cesarean sections.

# **AIMS AND OBJECTIVES**

# AIMS AND OBJECTIVES

#### AIM:

Our aim is to assess the effectiveness of using low-dose local anesthetics combined with an opioid in order to minimize the side effects typically associated with these local anesthetics.

#### **OBJECTIVE**:

#### **PRIMARY OBJECTIVE:**

- To evaluate and compare the sensory and motor block characteristics, as well as hemodynamic changes, of hyperbaric bupivacaine and levobupivacaine.
- To determine the duration of the block when fentanyl is added.

#### **SECONDARY OBJECTIVE:**

To evaluate side effects such as cardiotoxicity and neurotoxicity associated with bupivacaine and levobupivacaine.

# **REVIEW OF LITERATURE**

- <u>Gulen Guler *et al*</u> evaluated the effectiveness of levobupivacaine and hyperbaric bupivacaine for spinal anesthesia in cesarean sections, noting that levobupivacaine presents a lower risk of cardiotoxicity and neurotoxicity. They divided 60 patients into two groups: one receiving hyperbaric bupivacaine and the other receiving isobaric levobupivacaine, with 25 mcg of fentanyl added to both groups. They found that levobupivacaine combined with fentanyl could be an excellent alternative to bupivacaine for elective cesarean sections due to a shorter motor block time and fewer side effects such as hypotension, bradycardia, and nausea<sup>3</sup>.
- <u>Ak Singh *et al*</u> aimed to assess the efficacy and safety of isobaric levobupivacaine versus hyperbaric bupivacaine in lower limb orthopedic surgeries. The prospective, double-blinded cross-sectional study included 70 patients and compared the two anesthetics, finding that while bupivacaine had a faster onset of action, levobupivacaine resulted in a shorter duration of motor blockade<sup>4</sup>.

- <u>Z, Kazak *et al*</u> sought to determine the effectiveness of perianal or saddle block using two different doses of hyperbaric levobupivacaine by evaluating reliability, anesthesia satisfaction, voiding time, and hospital stay in anal surgery with spinal anesthesia. In this double-blinded prospective study involving 78 patients aged 30 to 75 years, hyperbaric levobupivacaine was found to cause less motor blockade and faster dermatome regression, facilitating early ambulation and a shorter hospital stay, which is advantageous for outpatient surgery<sup>5</sup>.
- J.F Luck et al conducted a study in 60 patients, and compared the clinical characteristics of 'hyperbaric' bupivacaine with their isomers levobupivacaine and ropivacaine<sup>6</sup> in spinal anesthesia. They found no significant differences between the three drugs, except that ropivacaine demonstrated more reliable action and a shorter duration of motor blockade.
- *Akcaboy EY et al,* evaluated the clinical effectiveness and quality of block of low-dose levobupivacaine against the low-dose bupivacaine when both were combined with fentanyl in transurethral resection of the prostate surgery<sup>7</sup>.

- Capelleri et al, aimed to compare the unilateral spinal block produced by small doses of hyperbaric ropivacaine with hyperbaric levobupivacaine in 91 ASA I-II patients undergoing knee arthroscopy. Both groups provided adequate analgesia, but ropivacaine resulted in a shorter motor blockade, facilitating early discharge<sup>8</sup>.
- M Mantouvalou et al, did a comparative study of the anesthetic efficacy and safety of three local anesthetic agents: racemic bupivacaine and its two isomers, ropivacaine and levobupivacaine, in patients undergoing lower abdominal surgery. The study concluded that the ropivacaine was the fastestacting isomer and that bupivacaine required more use of vasoactive drugs compared to ropivacaine and levobupivacaine<sup>9</sup>.
- **Deori et al,** compared the clinical effects (sensory block, motor block, hemodynamic effects, Apgar scores at 1 and 5 minutes, and adverse effects if any) of intrathecal 2.5 ml 0.5% isobaric levobupivacaine with 2.5 ml 0.5% hyperbaric bupivacaine for spinal anesthesia in lower segment cesarean sections. The study concluded that isobaric levobupivacaine provided better hemodynamic stability and faster mobility<sup>10</sup>.

- Valery Piacherski et al, compared the clinical efficacy of spinal anesthesia using 0.5% isobaric bupivacaine, 0.5% isobaric levobupivacaine, and 0.5% hyperbaric bupivacaine<sup>11-12</sup>. They found that levobupivacaine had the slowest development of sensory and motor block, while isobaric bupivacaine and levobupivacaine provided the longest postoperative analgesia<sup>11</sup>.
- Goel S et al, emphasized that the most often used local anesthetic in day care procedures is bupivacaine, and that higher intrathecal bupivacaine dosages might cause a greater degree of sensory and motor block, which can cause arterial hypotension and postpone hospital discharge. The minimal effective intrathecal fentanyl dose that, in conjunction with lowdose intrathecal bupivacaine, can provide sufficient surgical conditions without causing a prolonged recovery period was also assessed. They concluded that fentanyl 12.5 µg added to low-dose bupivacaine provided better surgical anesthesia with early mobility<sup>12</sup>.
- HC Coppejans et al, aimed to compare bupivacaine with newer local anesthetics in equipotent doses combined with opioids for epidural and spinal anesthesia in elective cesarean sections. The research verified that the more recent local anesthetics may be used effectively and result in less motor blockage. Even yet, ropivacaine needed a dosage that was at least 50% more than that of bupivacaine or levobupivacaine<sup>13</sup>.

15

- Gunusen et al, identified levobupivacaine as the most commonly recommended local anesthetic for elective cesarean sections. The study looked at the block's properties, clinical effectiveness, the surgeon and patient's level of satisfaction, and the hemodynamic effects of various intrathecal plain levobupivacaine doses mixed with fentanyl, which prolongs parturients analgesia<sup>14</sup>.
- Huang YF et al, did a comparison of the cardiovascular and central nervous system toxicity of levobupivacaine and bupivacaine among the sheep. They observed that levobupivacaine is less cardiotoxic, offering a greater safety profile<sup>15</sup>.

*Casimiro et al*, examined the anesthetic epidural effects of levobupivacaine plus fentanyl against bupivacaine plus fentanyl in patients having lower limb surgery. They found no significant difference between the two groups, but the levobupivacaine group experienced a shorter duration of motor blockade<sup>16</sup>.

## **CLINICAL ANATOMY**

#### SPINAL ANAESTHESIA

#### Definition

Spinal anesthesia involves injecting a local anesthetic into the subarachnoid space, temporarily interrupting nerve transmission<sup>17</sup>.

#### History

The term "spinal anesthesia" was coined by Leonard Corning in 1885 during his experiments with cocaine to address neurological issues<sup>18</sup>. His initial trials, beginning with a dog, resulted in temporary hind limb paralysis. Later, he administered the anesthesia to a human subject, initially with no effect, but successfully achieving numbness on a subsequent attempt. Corning's early work suggested the dog received spinal anesthesia, while the human likely received an epidural.

August Bier introduced modern spinal anesthesia in 1899 when his assistant<sup>19</sup>, Dr. Hildebrandt, underwent a lumbar puncture. Despite initial difficulties, they persisted, and within 23 minutes of injection, observed complete sensory and motor block<sup>20</sup>.

17


#### Anatomy

The spine consists of vertebral bones and fibrocartilaginous intervertebral discs, providing structural support and protecting the spinal cord and nerves. Each vertebral level has pairs of spinal nerves.

The spine forms a double C shape, convex anteriorly in the cervical and lumbar regions. Vertebrae are connected by fibrocartilaginous joints anteriorly and zygapophyseal joints posteriorly, with the central disc containing the nucleus pulposus<sup>21</sup>.


Notably, the thoracic spine has steeply angled spinous processes compared to the horizontal angulation of the lumbar spine, crucial for needle insertion.

#### Figure number 1: Number of spinal nerves




While the ligamentum flavum, interspinous ligament, and supraspinous<sup>22</sup> ligament give dorsal stability, the anterior and posterior longitudinal ligaments provide ventral support. The needle goes through these dorsal ligaments as well as the gaps between the next vertebrae's spinous processes and bony lamina when using a midline approach.





The spinal canal houses the spinal cord, its coverings (pia mater, arachnoid mater, and dura mater), fatty tissue, and a venous plexus. Cerebrospinal fluid (CSF) resides in the subarachnoid space.



#### Figure 3: Anatomy of spinal cord


#### **Spinal cord**

In adults, the spinal cord extends from the foramen magnum to the level of L1, and in infants, to the level of L3. The spinal cord terminates at conus medullaris, continued by filum terminale (fibrous extension) and cauda equina (neural extension).

#### **Blood supply**

- **1. Anterior spinal artery** originating from the vertebral artery, supplies anterior 2/3<sup>rd</sup> of the spinal cord.
- 2. Posterior spinal artery originating from the posterior inferior cerebellar artery, supplies posterior 1/3<sup>rd</sup> of the spinal cord.
- 3. Segmental arteries originate from intercostal and lumbar arteries.
- 4. Artery of Adamkiewicz<sup>23</sup> is one major branch variably entering between T7 and L4 on the left side and supply anterior 2/3<sup>rd</sup> of the spinal cord in lower thoracic and lumbar regions.

These arteries enter the spinal canal through each intervertebral foramen, where they branch out to supply the nerve roots and the spinal cord with medullary branches.<sup>24</sup>.



#### Figure number 4: Blood supply of spinal cord

#### **Mechanism of action**

When injected intrathecally local anesthetics primarily bind to the spinal nerve roots and peripheral spinal cord regions. Rostral spread occurs via arterial pulsations from the skull, with lesser amounts reaching the central spinal cord region. Blockade of efferent motor and autonomic transmission results from anterior nerve fiber blockage, while somatic and visceral impulses are blocked by posterior nerve fiber blockade<sup>25</sup>.

#### Somatic blockade

Spinal anesthesia achieves dense sensory and motor block with minimal anesthetic dose and volume. Smaller sympathetic fibers are more susceptible to blockade compared to larger sensory and motor fibers. Factors influencing drug penetration and uptake include drug mass, concentration of drug in CSF, the contact surface area, content of lipid, vascular supply of the local tissue, and size of the nerve root <sup>25</sup>.

Clinical progression of differential nerve block in order is -

- 1. Autonomic fibres sympathetic blockade occurs at two to six segments higher than the sensory block
- 2. Sensory fibres cold > warm > pinprick >pain >touch >pressure
- 3. Motor fibres two to three segments below the sensory block is when the motor block happens.

Differential nerve block depends on the following factors:

- Fiber arrangement in the nerve bundle
- Fiber diameter
- Inherent nerve fiber activity
- Variability in agent spread,
- Effects on ion channels other than Na+
- The specific local anesthetic drug used.

#### Autonomic blockade:

Spinal anesthesia predominantly blocks sympathetic and to a lesser extent, parasympathetic efferent transmission. Thoracolumbar is the sympathetic outflow; craniosacral is the parasympathetic outflow. Nonetheless, the neuraxial aneasthesia has no effect on the vagus nerve<sup>25</sup>.

# **PHYSIOLOGICAL EFFECTS**

#### Cardiovascular system:

Physiological effects of the spinal anesthesia resemble those induced by a combination of alpha 1 and beta-adrenergic receptor actions. Activation of beta 2 receptors leads to vasodilation, causing peripheral blood pooling and reduced venous return. This reduction in venous return subsequently decreases cardiac output. Sympathectomy predominantly induces venodilation due to the limited presence of smooth muscle in venules<sup>26</sup>.

The primary causes of hypotension following spinal anesthesia are decreased cardiac output and systemic vascular resistance. Bradycardia may occur due to reduced right atrial filling or involvement of cardioaccelerator fibers from T1 to T4.

In case of hypotension –

- Trendelenburg position and leg elevation
- Oxygen supplementation
- Crystalloids and colloids administration
- Vasopressors like ephedrine, phenylephrine
- Atropine for bradycardia

#### **Respiratory effects:**

In healthy patients, pulmonary function remains largely unchanged with neuraxial blockade. Spinal anesthesia at mid-thoracic levels (without affecting the phrenic nerve) results in minimal or no alteration in tidal volume, respiratory rate, minute ventilation, or arterial blood gases<sup>27</sup>. Hemodynamic resuscitation can relieve apnea even in cases of complete spinal anesthesia, indicating that the reason may be brain stem hypoperfusion rather than phrenic nerve block.

However, caution is warranted when using neuraxial blocks in patients with respiratory compromise, as paralysis of respiratory muscles can impair effective coughing and secretion clearance<sup>20</sup>, particularly affecting expiratory muscles.

#### **Gastrointestinal effects:**

Spinal anesthesia induces sympathetic blockade, leading to increased parasympathetic activity and subsequent gastrointestinal hyperperistalsis. This may cause patients to experience nausea and vomiting.

Hepatic blood flow decreases with reductions in mean arterial pressure resulting from any anesthesia technique<sup>28</sup>.

#### **Renal function:**

Neuraxial blockade accompanies a decrease in renal blood flow, though the decline is not clinically significant. When perioperative urinary catheterization is unnecessary, it is advisable to use the smallest effective dose of short-acting drugs required for the surgical procedure and to limit intravenous fluid administration. Monitoring for urinary retention is essential postoperatively to prevent bladder distension following spinal anesthesia<sup>21</sup>.

#### Central nervous system effects:

In neuraxial blockade there is reduced coronary blood flow, increased cerebral vascular resistance which reduces cerebral perfusion. no significant changes observed.

#### Metabolic and endocrine effects:

Surgery induces a neuroendocrine response characterized by the release of various substances. Neuraxial blocks effectively attenuate this response by reducing catecholamine release, potentially decreasing perioperative arrhythmias and ischemic events.

#### TECHNIQUE

#### **Preparation:**

- Explain the procedure to patient in brief
- Secure IV cannula with a large bore needle(20G/18G)
- Standard monitors to be attached
- Resuscitation equipment should be kept ready

#### Equipment

A standard spinal needle comprises a hub, a shaft terminating in a tip, and often includes a stylet.

The typical shaft length of a spinal needle is 9cm.

Various spinal needles are available, which can be classified according to:

i. Size of the needle –

Sizes are available from 18 to 30G. Large gauze spinal needles improves tactile sensation of needle placement, whereas complications related to CSF leaks and post dural puncture headache are less with finer needles.

- ii. Shape of spinal needle tip
  - 1. Dura cutting needles
  - 2. Dura splitting needles


#### Dura cutting needles-

These needles are bevelled tips with cutting edges Cuts longitudinally aligned dural fibres It causes more CSF loss and more likely to cause PDPH Examples: Quincke, Atraucan, Greene.

#### Dura splitting needles-

These are also called as pencil point tip needles. The aperture is on the side of the shaft and require more time to insert. Less amount of tissue coring and less likely to cause PDPH. Examples: Whitacre, Sprotte, Eldor

#### Figure number 5: Common tip designs for spinal needles



# 1. Drug Factors

# Mechanism of drug spread:

There are several factors which contribute to the level of blocka after a spinal anaesthesia. They are

# Characteristics of the injected solution:

# 1. Baricity:

Baricity refers to the density of local anesthetic solution relative to the density of cerebrospinal fluid (CSF), which is approximately 1.00059 g/liter. Solutions are classified based on their density:

- Hypobaric density < 1
- Isobaric density = 1
- Hyperbaric density >1, Hyperbaric drug spread is more predictable hence it is made hyperbaric by adding dextrose.
- Gravity significantly influences the spread of hyper- and hypobaric solutions.

# 2. Volume, dose and concentration:

- These factors are interconnected, with dose being the most critical determinant of local anesthetic spread<sup>29</sup>.
- Volume \* concentration = dose

# 3. Addition of other drugs:

- Vasoconstrictors Vasoconstrictors prolong the duration of action by reducing systemic absorption, thereby enhancing the retention of the drug in the subarachnoid space<sup>30</sup>.
- Opioids Opioids, when added to local anesthetics, exert a synergistic effect without affecting motor blockade.

# 2. Patient factors


- Age Advancing age correlates with reduced conduction velocity, axonal degeneration, fewer nerve fibers, and diminished CSF volume.
   Consequently, elderly patients require lower doses as the block height increases.
- Height Height influences anesthesia spread, especially in cases of extreme variation.
- Weight BMI affects anesthesia distribution; obese patients may experience increased spread due to reduced volume of CSF.
- ✤ Position –

# **<u>1.</u>** Lateral decubitus with universal flexion:

Patient should be positioned with their back parallel to the OT table axis, thighs flexed upward, and neck forward (fetal position).

Head high/head low positioning can be utilized to leverage the baricity of spinal local anesthetics<sup>31</sup>.

# Figure number 6: Lateral decubitus with universal flexion




# **<u>2.</u>** Sitting position:

The patient sits upright, back parallel to the OT table axis, feet supported, head flexed, arms supporting a pillow over the chest, and arching their back (C-shaped position).

This maximizes intervertebral space opening<sup>32</sup>.


# Figure number 7: Sitting position for spinal anesthesia



# **<u>3.</u>** Prone position:

The prone position is used when the patient will be in this position for the surgical procedure (rectal, perineal and lumbar procedures). Hypobaric LAs are administered. Patient positions self, lumbar lordosis has to be minimized, a paramedian approach is often used<sup>33</sup>.

Figure number 8: Prone position for spinal anesthesia



# **3.Procedures factors**

#### 1. Patient position:

The baricity of the local anesthetic drug and the patient's posture both affect the degree of block. Whereas hypobaric solutions tend to ascend, hyperbaric solutions tend to settle downward.

# 2. The injection level:

A larger spread is obtained by injecting with the plain solutions at higher levels.

# 3. Type of needle:

Use of directional needles can influence the spread of anesthesia based on the direction of the needle aperture.

# 4. Technique of injection:

This technique involves repeated aspiration of CSF and reinjection of the local anesthetic.

#### Rate of injection:

Rapid injections result in marked diffusion, leading to higher levels of blocks.

# 5. Characteristics of spinal fluid:

Factors such as volume, density, and pressure of CSF play a role in anaesthesia spread.

## 4. Projection and puncture

After ensuring the patient is correctly positioned, it is crucial to follow strict aseptic procedures. Betadine, a povidone-iodine solution, should be used to clean the back. Let it sit on the skin for at least two minutes, then wipe it off with dry gauze and cover it. Drawn between the iliac crests' greatest points, Tuffier's line typically corresponds to either the L4-L5 interspace or the L4 vertebral body. The subarachnoid space can be accessed in two ways:

# Midline approach-

- Advantages include an anatomically straightforward projection and a relatively avascular plane.
- The spinal needle is inserted midline, at a 15-20 degree cephalad angle, with the bevel parallel to the dura's longitudinal fibers, after local infiltration with 2% lignocaine.
- The dorsal to ventral structures that are punctured are the dura, supraspinous ligament, interspinous ligament, and skin.
- Upon passing through the ligamentum flavum and dura, there are noticeable "giveaways" or pops. The needle is placed in the subarachnoid space following the second giveaway. Following placement confirmation via CSF aspiration, 0.2 ml/s of local anesthetic is given.

# Paramedian approach-

- This approach avoids anatomical limitations imposed by the spinous process by placing the needle laterally.
- Aim for the midline 1 cm from the spinal needle, 10-15 degrees off the sagittal plane, in line with the mid space. As development proceeds, the dura gives way characteristically and CSF is acquired.

# Contraindications of spinal anaesthesia:

# Absolute

- Significant coagulopathy
- Localized sepsis
- Raised intracranial pressure
- Severe untreated hypovolemia
- Valvular heart diseases- fixed output lesions/stenotic lesions
- Septic shock
- Severe anemia
- Arachnoiditis, meningitis

# Relative

- Neurological deficits and demyelinating diseases
- Spinal deformities
- Sepsis
- Thromboprophylaxis
- Inherited coagulopathy

# **PHYSIOLOGY OF PAIN**

Pain can be acute or chronic. It can be a result of any injury, underlying morbidity, abnormal function of any organ. Long standing disease usually cause chronic pain. The visceral pain which is experienced at a location away from its actual site is called as referred pain due to the same embryological origin.

#### Pain has four components-

- Sensory-conscious perception
- Motor- withdrawal reflex
- Autonomic-tachycardia, perspiration
- Affective-anger


#### Changes in each organ system due to pain are-

- Heart-tachycardia, hypertension, arrhythmias
- Lungs-oxygen consumption is increased, increase in respiratory rate
- Blood-thrombosis
- Gut-decreased gut motility, ulceration, urinary retention
- Endocrine-increased catecholamines
- Immunology-increased total count
- Psychology-anger, anxiety, decreased sleep

# GATE THEORY

Ronald Melzack and Patrick wall, explained this theory. Here, the pain stimulus is not experienced if there is simultaneous stimulation by inhibitory impulses as well.

Pain is delivered by A-delta and C fibers. A-beta fibres can override the pain stimulus by delivering information about touch and pressure simultaneously. Brain can decrease the pain intensity by activating endogenous pain suppression pathways. Neurotransmitters involved are serotonin and enkephalin.



#### **Figure number 9: Pain pathway**

# LOCAL ANAESTHETICS

Karl Coller introduced Cocaine in 1884, the first used local anaesthetic. These drugs cause reversible nerve blockages and decreases nerve sensation. They are used to decrease perioperative stress, for early recovery and to treat dysrhythmias.


The resting membrane potential of a nerve fibre is -60 to -70 mv. The main action of these drugs is by inhibiting voltage gated sodium channels, thereby preventing the influx of sodium through these channels. This delays the depolarization causing no action potential. Small diameter nerves are blocked before large diameter nerves. Myelinated nerves are more sensitive than the non-myelinated nerves. The Minimum Effective Concentration (Cm) is the lowest quantity of local anaesthetic required to block the nerves impulses.

Sodium channels have alpha and the beta subunits. They exist in three stages open, closed, resting. Drugs bind the channels when they are in open state.

More the depolarization, more the probability of sodium channel blockade by the local anaesthetics. This is called as frequency or user dependent blockade. Motor fibres have twice the 'Cm' as that of sensory fibres. The A fibres and C fibres vary in diameter. The similar concentrations of local anaesthetics block both of them. The structure of the local anaesthetics contains two groups. A lipophilic group and a hydrophilic group. These two groups are linked by an ester or amide linkage. Depending upon this link they are classifies as esters and amides. Pseudocholine esterase enzyme metabolizes esters and amides by the liver.

pKa is the pH at which there are equal amounts of unionized and ionized molecules. The drugs having low lipid solubility and less potency acts faster. Addition of sodium bicarbonate makes the drug more alkaline, making the onset faster.





# PHARMACOLOGY OF BUPIVACAINE


# History

It is a widely used local anaesthetic drug, first synthesized by Ekenstam in 1957. It was used clinically by LJ Telivuo in 1963.

It is longacting amide type local anaesthetic chemically related to lignocaine and mepivacaine. It has two groups namely, an aromatic ring attached to a tertiary amine by an amide link. The aromatic ring gives lipophilic character. It is four times more potent than lignocaine.

The pKa value at 25degree celcius is 8.1, at physiological pH of 7.4, 15% is in unionized form and 85% is ionized.

# Figure number 11: Chemical structure of bupivacaine



# **Pharmacokinetics:**

#### Absorption

- The uptake of bupivacaine from its site of injection depends on-
- The drug concentration
- Volume of the drug
- Vascularity of the area
- Route of administration of the drug

# Distribution

Bupivacaine is distributed throughout all body tissues, with varying concentrations in different organs; highly perfused organs exhibit higher concentrations compared to less perfused ones. It is rapidly cleared by lung tissue, causing a marked decrease in blood concentration as it passes through the pulmonary vasculature. The terminal half-life is approximately 30 minutes, and the steady-state volume of distribution is 72 liters.

#### **Metabolism and excretion**

Bupivacaine undergoes enzymatic degradation primarily in the liver. The main metabolic pathway involves N-dealkylation to pipecoloxylidine. Additional metabolites include N-desbutyl bupivacaine and hydroxy bupivacaine. Approximately 5% is excreted as pipecoloxylidine in urine, and 16% is excreted unchanged in urine. Clearance is approximately 7 ml/kg/min. Bupivacaine exhibits high plasma protein binding, predominantly to alpha-1 acid glycoprotein, with a binding capacity of 95%.

#### **Pharmacological actions**

Bupivacaine was the first local anesthetic noted for intermediate speed of onset of action with a long duration of action, and profound conduction block, with a significant separation between sensory and motor blockade.

#### **Onset of action-**

The onset of action is determined by pKa of individual agents since unionized form is local anaesthetic is responsible for diffusion across the nerve membranes. The amount of bupivacaine present in the unionized form is inversely proportional to its pKa. Hence bupivacaine has intermediate position in terms of pKa and latency of blockade. In vivo latency is also dependent on the concentration of drug used. 0.25% bupivacaine has slow onset of action but increasing to 0.75% results in increased anaesthetic effect.

#### **Duration of action-**

Duration of action is related to degree of protein binding because conduction blockade is believed to occur after the interaction with protein receptor within its protein receptor within the sodium channel. Compounds which have a greater affinity and bind more firmly to the receptor cause prolonged duration of block. Bupivacaine is removed extremely slow from the isolated nerves hence it has prolonged duration of action.

#### SYSTEMIC EFFECTS

Maximum dose of bupivacaine is 3mg/kg. It produces systemic effects after absorption. The rate and extent of absorption depends on dose, site of injection, volume and physiochemical properties of the drug. Bupivacaine is lipid soluble, more potent with less systemic absorption.

#### Central nervous system:

Bupivacaine crosses the blood-brain barrier, and systemic absorption or direct intravascular injection can lead to CNS toxicity. Dose-dependent effects include light-headedness, tinnitus, circumoral numbness, tongue paresthesia, seizures, unconsciousness, coma, respiratory arrest, and cardiovascular depression. In comparison to lidocaine (7.1), bupivacaine (3.5) has a reduced ratio of cardiovascular collapse (CC) to CNS toxicity (CC/CNS).

#### Cardiovascular system:

Bupivacaine depresses myocardial automaticity, shortens the refractory period, and reduces myocardial contractility and conduction velocity at higher concentrations. These effects are primarily due to direct blockade of cardiac Na+ channels and inhibition of the autonomic nervous system. Bradycardia, heart block, and hypotension may lead to cardiac arrest. High protein binding of bupivacaine complicates resuscitation efforts, especially in cases of pregnancy, respiratory acidosis, and hypoxemia.

# **Respiratory system:**

Bupivacaine decreases the hypoxic drive. Apnea may result from phrenic nerve or intercostal nerve paralysis or by the depression of medullary respiratory center.

#### Hematological system:

Bupivacaine decreases coagulation, decreases platelet aggregation, enhances fibrinolysis and prevents thrombosis. Embolic events are reduced in patients receiving epidural bupivacaine.

# **ADVERSE EFFECTS:**

Bupivacaine is relatively free of adverse effects when administered in appropriate doses. However systemic toxicity may occur when injected intravascularly or in large doses.

# **Toxicity:**

**CNS:** Circumoral numbness, parasthesia, dizziness, tinnitus, blurred vision, followed by CNS excitatory features like restlesseness, agitation, tonic clonic seizures, followed by CNS depression like drowsiness, unconsciousness, coma, respiratory arrest.

**CVS:** Hypotension, AV block, dysrhythmia such as ventricular fibrillation, cardiac arrest.

**Allergic reactions:** Very rare. The preservative methylparaben may be responsible for the allergic reactions.

**Musculoskeletal:** Bupivacaine is myotoxic and can cause cystic degeneration, oedema and necrosis on direct injection in skeletal muscle.


# PHARMOCOLY OF LEVOBUPIVACAINE

Levobupivacaine is the S (–) isomer of racemic bupivacaine, exhibiting similar physicochemical properties. It is highly protein-bound, lipid-soluble, and shares a comparable pKa to bupivacaine.

Levobupivacaine's S enantiomer has exactly the same physicochemical characteristics, however it may have a different affinity for the site of action or have different adverse effects. The S-enantiomer exhibits significantly less neurological and cardiac damage than the R-enantiomer due to the enantiomer's distinct affinity for sodium, potassium, and calcium channels.

Levobupivacaine is as potent as bupivacaine and produces similar sensory and motor block. Some studies have shown more sensory blockade and less motor blockade compared to bupivacaine which may be related to the higher vasoconstrictive activity of levobupivacaine than that of R (+) enantiomer (dexbupivacaine) at lower doses<sup>34</sup>.

#### Figure number 12: Chemical structure of levobupivacaine



# **Pharmacokinetics**

#### Absorption

It depends on the route of administration, vascularity of the tissue, dose, volume and concentration. Absorption of epidural levobupivacaine is biphasic and influenced by factors such as age and drug concentration. Older patients may experience broader analgesic spread, up to three dermatomes, necessitating reduced dosing<sup>35</sup>.

# Distribution

Levobupivacaine is extensively bound to plasma proteins and widely distributed throughout the body.

# **Metabolism and excretion**

Hepatic cytochrome P450 enzymes metabolize levobupivacaine to form 3hydroxylevobupivacaine and desbutyl-levobupivacaine. Metabolites are excreted in the urine as glucuronic acid and sulfate ester conjugates.

#### **Adverse effects**

#### **CNS**:

Levobupivacaine induces less neurotoxicity compared to bupivacaine, yet CNS toxicity symptoms are similar. Its uptake by CNS cells is enantio-selective, enhancing safety profiles. Many animal models show that the convulsive threshold is higher than that of bupivacaine<sup>36</sup>, which results in less CNS symptoms and excitatory alterations in the electroencephalogram in human volunteers following intravenous injection.

#### **CVS**:

The S (-) isomer exhibits weaker potassium channel blocking potency, reducing the likelihood of QTc interval prolongation. Stereoselective binding to sodium and potassium channels decreases the inhibitory effects, thereby lowering the overall toxicity potential compared to bupivacaine.

# **MATERIALS AND METHODS**

- Source of data: This research was carried out in the Department of Anaesthesiology at B.L.D.E (Deemed to be University) Shri B. M. Patil Medical College, Hospital, and Research Centre, Vijayapura.
- **Study design**: This is a randomized double blind prospective comparative study.
- Study period: This study was conducted from September 2022 to march 2024
- Study population: This study will be done in 130 randomly selected parturient women scheduled for elective cesarean delivery of more than 37 weeks gestation, who belong to ASA (American society of anesthesiologist) class 1 and 2.
- Statistical Analysis:
- The Statistical Package for the Social Sciences (SPSS), Version 20, was used to analyze the data, which was entered into Microsoft Excel.
- Bar graphs, percentages, and Mean±SD were used to express the results.
- The independent t-test was applied for normally distributed continuous variables.
- The Mann-Whitney U test was used for non-normally distributed variables.
- The chi-square test was employed for categorical variables.
- A p-value of less than 0.05 was considered statistically significant.

# **INCLUSION CRITERIA:**

- 1. Women more than 37 weeks period of gestation
- 2. ASA class I and II
- 3. Scheduled for elective cesarean delivery

# **EXCLUSION CRITERIA:**

- 1. Refusing regional anaesthesia.
- 2. Having contraindications to spinal anaesthesia.
- 3. Body weight more than 100kg
- 4. Shorter than 150cm
- 5. Taller than 175cm
- 6. Women receiving medications other than perinatal vitamin, calcium, proteins and iron.
- 7. Mothers with previous Systemic diseases.
- 8. Expected mothers with foetal anomaly, placenta previa, abruption placenta.

# METHODOLOGY

# Preliminaries

- Written informed consent is taken.
- Nil per oral status confirmed.
- Intravenous access is secured with a 20gauge cannula.

# **Preanesthetic evaluation:**

- Before taking the patient for surgery, detailed history, general and systemic examination is carried out the previous day.
- History of any significant medical illness is elicited and medication history taken.
- Airway, respiratory system and cardiovascular system are assessed.

# **Investigations:**

- Complete blood count, Bleeding time, Clotting Time.
- Blood sugars.
- Serology.

#### PROCEDURE

- Patients are assessed preoperatively, nil per oral status confirmed on the day of surgery.
- Intravenous access is gained using a 20gauge iv cannula and Ringer's lactate fluid is started at 15ml/kg/hour.
- After shifting to surgical table standard monitoring devices like pulse oximetry, noninvasive blood pressure, ECG leads are attached and baseline values are recorded.

- Then patients are placed in left lateral decubitus position, under aseptic precautions painting and draping are done.
- Then subcutaneous infiltration is done with 1-2 ml of 2% lignocaine at L3-L4 interface.
- Then lumbar puncture is performed with 26G quincke's spinal needle and subarachnoid space is identified.
- Patients are randomly divided into two groups
  - Group BF 65 patients belonging to ASA class 1 and 2 received 10mg 0.5% (2 ml) of hyperbaric bupivacaine with 25mcg (0.5 ml) fentanyl.
  - Group LF 65 patients belonging to ASA class 1 and 2 received 10mg 0.5% (2 ml) of hyperbaric levobupivacaine with 25mcg (0.5ml) fentanyl.
- Two group administered intrathecally within the 10 seconds.
   Subsequently, patients were turned to supine position. Oxygen at 4 L/min was administered through a facial mask.
- The sensory level of spinal anesthesia was assessed bilaterally in the mid clavicular line by pinprick, cold swab and motor level assessment with Bromage scale.
- Surgeons were permitted to operate once level of T4 to T6 is achieved.
- Spinal anesthesia Time will be noted and the following parameters are recorded every 2minutes from time 0 for the initial 60 minutes, then monitored every 30minutes till completion of surgery and every hourly for 24 hours.

# Parameters:

- Pulse rate (PR)
- Systolic blood pressure (S.B.P.)
- Diastolic blood pressure (DBP)
- Mean Arterial pressure (M.A.P.)
- Oxygen saturation (SpO2)
- Using the intrathecal injection time as time zero, the duration of the sensory block, the time it takes to achieve its maximum level, the time it takes for the two dermatomes of the block to regression, and the time to initiation of the sensory block.
- It is noted when the sensory block level reverses from the maximum level to T12. The modified Bromage scale is used to measure the degree of motor block.
- Onset of sensory block was considered as duration between time of study drug given and loss of pain prick test at T10 dermatome level.
- Time of 2 segment regression of sensory block was taken as duration between time of onset of sensory block at T10 and sensory block regression to T12 dermatome level.
- Duration of sensory block was taken as duration between time of onset of sensory block and sensory block regression to S2 dermatome level.
- The time interval from study drug injection to motor paralysis equal to a Bromage score of 3 was used to determine the onset of motor block.
- From the moment a motor block started until all motor function returned to a Bromage score of 0, that was the duration of the motor block.
- Episode of bradycardia
- Episode of hypotension
- Episode of nausea and vomiting
- Adverse effects like shivering, itching, headache is noted.
- APGAR score noted at 1 minute and 5 minutes.

# INTERPRETATION: CHARACTERISTICS OF ANESTHESIA:

#### SENSORY BLOCK

- 1. Onset of sensory block
- 2. Time to reach T10 level.
- 3. Time to reach T4 level.
- 4. Time for regression of two dermatomes.
- 5. Total duration of sensory block.

# **MOTOR BLOCK**

- 1. Onset of motor block.
- 2. Time to reach maximum level.
- 3. Total duration of motor block.

# **DURATION OF ANALGESIA**


#### **SIDE EFFECTS:**

Hypotension, bradycardia, headache, backache, nausea, vomiting, itching, sedation, shivering.

#### **MODIFIED BROMAGE SCALE**

- 0 = No block
- 1 = Inability to raise extended leg
- 2 = Inability to flex knee
- 3 = Inability to flex ankle and foot

# Figure number 13: Visual analogue scale (VAS)



# **OBSERVATION AND RESULTS**

- This randomized double blind prospective comparative study was done on 130 parturients, belonging to ASA class 1 and 2, who is undergoing elective cesarean sections in B M patil medical college, Vijayapura from September 2022 to march 2024. Patients were randomized into 2 groups to receive hyperbaric bupivacaine and hyperbaric levobupivacaine.
- Group BF (n=65) received 2ml of hyperbaric bupivacaine 0.5% with 25mcg of fentanyl as additive.
- Group LF (n=65) received 2ml of hyperbaric levobupivcaine 0.5% with 25mcg of fentanyl as additive.
- Data was entered in Microsoft office excel sheet and was analyzed by standard statistical software.
- The results were summarized by routine descriptive statistics namely mean and standard deviation for numerical variables and counts and percentage for categorical variables.
- Numerical variables are compared between groups by Mann-whitney 'U' test.
- Chi square test was employed for intergroup comparison of categorical variables. Analysis done was 2 tailed and p <0.005 was considered to be statistically significant.

# 1. AGE


The following table 1 and bar diagram (graph 1) describe the age distribution of the patients in group 1 and group 2.

The mean age was similar in both groups (25.23 + 4.63 in group 1 and 26.14 + 4.86 in group 2)

#### Table 1 comparison of age (years)distribution

	GROUP 1 GROUP 2		MANN	DVALUE		
	MEAN	SD	MEAN	SD	WHITNEY TEST	P VALUE
AGE	25.23	4.633	26.14	4.863	1840.5	0.204

# Graph 1 comparison of age (years) distribution



# 2. ONSET OF SENSORY BLOCK IN MINUTES


The following table 2 and graph 2 describe the mean onset of sensory block in group 1 and group 2.

The mean onset of sensory block was higher in group 2 levobupivacaine group (1.5131+/-0.86883) compared to group 1 bupivacaine group (1.1185+/-0.60023).

# Table 2 comparison of onset of sensory blocks in group 1 and group 2

	GROUP 1		GROUP 2			
ONSET OF SENSORY	MEAN	SD	MEAN	SD	MANN WHITNEY TEST	P VALUE
<b>BLOCK IN MINUTES</b>	1.1185	0.60023	1.5131	0.86883	1578.5	0.11

# Graph 2 comparison of onset of sensory blocks in group 1 and group 2



# 3. TIME TO REACH T10 IN MINUTES


The following table 3 and bar diagram graph 3 describe mean onset of time to reach T10 in minutes in group 1 and group 2

The mean onset of time to reach T10 in minutes is more in group 2 levobupivacaine group (1.9538+/-1.25) compared to group 2 bupivacaine (2.3015+/-1.1818).

# Table 3 comparison of time to reach T10 in minutes

TIME TO REACH T10 IN MINUTES	GROUP 1		GROUP 2		MANN WHITNEY		
	MEAN	SD	MEAN	SD	TEST	P VALUE	
	1.9538	1.25702	2.3015	1.1818	2027	0.517	

# Graph 3 comparison of time to reach T10 in minutes



# 4. TIME TO REACH T4 IN MINUTES


The following table 4 and graph 4 represents comparison of time to reach T4 in group 1 and group 2.

The means of comparison to reach T4 is slightly higher in group 1 bupivacaine group (0.846+/-2.89) compared to group 2 levobupivacaine (0.466+/-1.294)

# Table 4 comparison of time to reach T4 in minutes

	GROUP 1		GROUP 2		MANN	WHITNEY	Р
	MEAN	SD	MEAN	SD	TEST		VALUE
TIME TO REACH T4 IN MINUTES	0.846	2.8952	0.466	1.294	2027		0.517

# Graph 4 comparison of time to reach T4 in minutes



# 5. TIME OF REGRESSION OF DERMATOME


The following table 5 and graph 5 is comparison of regression of dermatome with group 1 and group 2.

The mean of regression shows significant difference between two group as p value is 0. The mean is higher in group 1 bupivacaine group (177.25+/-35.691) compared to group 2 levobupivacaine group (151.78+/-35.016).

#### Table 5 Comparison of regression of dermatome

	GROUP	GROUP 1		2			
	MEAN	SD	MEAN	SD	MANN W TEST	/HITNEY	P VALUE
TIME OF REGRESSION OF DERMATOME	177.25	35.691	151.78	35.016	2027		0

#### **Graph 5 comparison of regression of dermatome**



# 6. TOTAL DURATION OF SENSORY BLOCK


The following table 6 and graph 6 represents comparison of total duration of sensory block in group 1 and group 2.

The mean of comparison of total duration of sensory block is significantly more in group 1 bupivacaine group (194.6+/-30.543) compared to group 2 levobupivacaine group (166.78+/-31.978). p value is 0 which is significant.

 Table 6 Comparison of total duration of sensory block

	GROUP 1		GROUP 2		MANN WHITNEY	Р
TOTAL DURATION OF SENSORY BLOCK IN MINUTES	MEAN	SD	MEAN	SD	TEST	VALUE
	194.6	30.543	166.78	31.978	1085	0

# Graph 6 Comparison of total duration of sensory block



# 7. ONSET OF MOTOR BLOCK IN MINUTES


The following table 7 and graph 7 describes the comparison of onset of motor block in group 1 and group 2.

The mean of comparison of motor block in group 1 is (1.45+/-0.99) compared to group 2 (1.48+/-0.66).

# Table 7 Comparison of onset of motor block

	GROUP 1		GROUP 2				
	MEAN	SD	MEAN	SD	MANN TEST	WHITNEY	P VALUE
THE ONSET OF MOTOR BLOCK IN MINUTES	1.455	0.99	1.48	0.6636	1796		0.125

# Graph 7 comparison of onset of motor block



# 8. TIME TO REACH MAXIMUM LEVEL IN MINUTES


The following table 8 and graph 8 describes comparison between group 1 and group 2 the time to reach maximum level in minutes.

The mean of comparison of time to reach maximum level is similar in both groups. In group 1 it shows mean (2.7438+/-1.8255) and in group 2 it shows (2.834+/-1.1).

#### Table 8 comparison about time to reach maximum level in minutes

	GROUP 1		GROUP 2			
	MEAN	SD	MEAN	SD	MANN WHITNEY TEST	P VALUE
TIME TO REACH MAXIMUM LEVEL IN MINUTES	2.7438	1.8255	2.8354	1.1	1773.5	0.105

#### Graph 8 comparison about time to reach maximum level in minutes



# 9. DURATION OF ANALGESIA


The following table 9 and graph 9 describes comparison of total duration of analgesia in two groups which is significant as p value is 0.

The mean hour in group 1 bupivacaine (196.35+/-29.65) is longer duration compared to group 2 levobupivacaine (170+/-34.425).

# Table 9 Comparison of duration of analgesia

	GROUP 1		GROUP 2		MANN WHITNEY	Ρ
DURATION OF ANALGESIA IN HOURS	MEAN	SD	MEAN	SD	TEST	VALUE
	196.35	29.654	170.46	34.425	1318.5	0

# **Graph 9 Comparison of duration of analgesia**




#### **10.EPISODES OF HYPOTENSION**

The following table 10 and graph 10 describes the episode of hypotension in group 1 and group 2. The incidence of hypotension is slightly higher in group 1 bupivacaine group compared to group 2 levobupivacaine.

#### Table 10 Comparison of episodes of hypotension

	GROUP 1		GROUI	2		
	n	%	n	%	CHI SQUARE TEST	P VALUE
HYPOTENSION	28	43.1	20	30.8	2.114	0.146

# Graph 10 Comparison of episodes of hypotension




## **11.EPISODES OF BRADYCARDIA**

The following table 11 and graph 11 represents the comparison of episodes of bradycardia in group 1 bupivacaine and group 2 levobupivacaine. There is no significant difference between two groups.

## Table 11 Comparison of episode of bradycardia

	GROUP 1		GROUF	° 2	CHI SQUARE TEST	Р
BRADYCARDIA	n	%	n %		CHI SQUARE TEST	VALUE
	11	16.9	11	16.9	0	1

# Graph 11 Comparison of episode of bradycardia



## **12. EPISODES OF NAUSEA AND VOMITING**


The following table 12 and graph 12 depicts the comparison of episodes of nausea and vomiting in group 1 and group 2.

It shows episodes of nausea and vomiting is more in group 1 bupivacaine group compared to group 2 levobupivacaine group.

#### Table 12 Comparison of nausea and vomiting

		GROUP 1	G	ROUP 2		
						Р
	n	%	n	%	CHI SQUARE TEST	VALUE
NAUSEA						
VOMITING	23	35.4	11	16.9	5.735	0.017

## Graph 12 Comparison of nausea and vomiting



#### **13. EPISODES OF HEADACHE**


The following table 13 and graph 13 represents the comparison of episodes of headache in group 1 and group 2.

The comparison shows slightly more in group 1 bupivacaine group compared to group 2 levobupivacaine.

#### **Table 13 Episodes of headache**

	GROUP 1         GROUP 2         CHI SQUA           n         %         n         %         CHI SQUA           10         15.4         6         9.2         CHI SQUA		Р					
HEADACHE	n	%	n %			VALUE		
	10	15.4	6	9.2	1.146	0.286		

## Graph 13 Episodes of headache



# **14.EPISODES OF ITCHING**


The following table 14 and graph 14 describes the comparison of episodes of itching in group 1 and 2.

It shows significant higher number of itching in group 1 bupivacaine compared to group 2 levobupivacaine.

#### **Table 14 Comparison of itching**

	GRO	OUP 1	(	GROUP 2		Р
ITCHING	n	%	n	%	CHI SQUARE TEST	VALUE
	13	20	3	4.6	7.127	0.008

## **Graph 14 Comparison of itching**



## **15. EPISODES OF SHIVERING**


The following table 15 and graph 15 describes the comparison of episodes of shivering in group 1 and group 2.

It shows significant higher rate of shivering episodes in group 1 bupivacaine compared to group 2 in levobupivacaine.

#### **Table 15 Comparison of shivering**

		GROUP 1		GROUP 2		Р
SHIVERING	n	%	n	%	CHI SQUARE TEST	VALUE
	24	36.9	9	13.8	9.138	0.003

## **Graph 15 Comparison of shivering**



# DISCUSSION

- This study compares the effects of hyperbaric bupivacaine 10mg and hyperbaric levobupivacaine 10mg, both combined with 25mcg fentanyl, in elective cesarean sections. Both drug combinations produce similar quality in the onset of sensory and motor blockade, with comparable maternal hemodynamic and neonatal outcomes.
- However, levobupivacaine has a shorter duration of sensory and motor blockade compared to bupivacaine. Bupivacaine offers a longer duration of analgesia.
- Intrathecal opioids enhance the efficacy of local anesthetics in neuraxial blockade by increasing the duration of analgesia and promoting hemodynamic stability through dose reduction of the local anesthetics<sup>38</sup>.
- The duration of postoperative analgesia increases with higher doses of bupivacaine. Adding fentanyl to bupivacaine enhances postoperative analgesia, though it also prolongs motor recovery.
- Bogra et al. found that intrathecal fentanyl in elective cesarean sections creates a synergistic effect due to its rapid onset and short duration, with fewer respiratory issues<sup>39</sup>.
- Lee et al<sup>40</sup> reported that using levobupivacaine 0.5% with fentanyl in urological surgery is as effective as using levobupivacaine alone.
- Bidikar et al<sup>41</sup> compared levobupivacaine 0.5% 10mg with a lower dose plus fentanyl and found that the combination extended sensory block duration and delayed the need for additional analgesia without prolonging motor block.

- In a study by Atienzar et al <sup>42</sup> compared the analgesic efficacy of bupivacaine, levobupivacaine, and ropivacaine in labor analgesia, concluding all were effective but pain scores were higher with levobupivacaine. Motor block was more significant with bupivacaine.
- In a study by Bremerich et al<sup>43</sup> conducted study to compare hyperbaric bupivacaine 0.5% with hyperbaric levobupivacaine 0.5% with addition of opioid as either fentanyl 10mcg or 20 mcg or sufentanil 5mcg in order of sensory and motor block characteristics and analgesic effects. The study found that levobupivacaine produced shorter and a less pronounced motor blockade than the bupivacaine, regardless of the opioid added. No parturient experienced intraoperative pain. Adding sufentanil 5 µg to either local anaesthetic significantly prolonged duration of effective analgesia compared to supplemental fentanyl 10 or 20 µg.
- In a study by Esraa et al<sup>44</sup> compared levobupivacaine and bupivacaine in cesarean sections, finding that both provide adequate surgical anesthesia. Levobupivacaine intrathecally offers a safer option due to lower incidences of cardiotoxicity and neurotoxicity, although hypotension is common during spinal anesthesia due to CSF displacement caused by pregnancy-related engorgement of epidural veins.
- Hypotension is most common side effect seen with more than 50% of parturients during spinal anaesthesia, due to engorgement of epidural veins from aortocaval compression in pregnancy, which causes displacement of CSF and causes more cephalad spread of local anaesthetics. This increases risk of hypotension.
- In the current study, decreases in systolic and diastolic blood pressure were within acceptable ranges (bupivacaine group 43.1% and levobupivacaine group 30.8%).

- The incidence of hypotension was similar in both groups, with levobupivacaine plus fentanyl providing better hemodynamic stability. Hypotension is considered when SBP is less than 90mmhg.
- Bradycardia is produced when there is cephalad spread of blockade more than T4 level. The percentage of bradycardia is similar in both groups.
- Itching is most common side effects associated with addition of fentanyl. The adverse effects are more in bupivacaine group 20% compared to levobupivacaine group 4.6%. Shivering is also seen more in number in bupivacaine group 36.9% and in levobupivacaine group 13.8%.
- In our study the onset of sensorial and motor blockade is similar in both group without much significant difference, but duration of sensory and motor blockade is shorter with levobupivacaine.
- The duration of analgesia is increased with addition of fentanyl which provides synergistic effect with bupivacaine. Hence duration of analgesia is longer with bupivacaine group (196.35) compared to levobupivacaine group (170.46).
- The study which is comparing the study of fentanyl with bupivacaine and levobupivacaine in elective cesarean sections similar to our study is Goyal A et al<sup>45</sup>. They compared hyperbaric bupivacaine(10mg) with 25mcg fentanyl and isobaric levobupivacaine(10mg) with fentanyl 25mcg in elective cesarean sections.
- They assessed sensory and motor blockade characteristics with side effects associated with bupivacaine. Levobupivacaine with fentanyl in the study provides early ambulation in elective sections by reducing motor block time, reducing side effects such hypotension and bradycardia, and improving hemodynamic stability.
- In our study, the neonatal effects of both drug combinations were similar, as measured by APGAR scores at 1 and 5 minutes, indicating no significant impact of the opioids or local anesthetics on neonates<sup>46</sup>.

# SUMMARY

Our study's objective was to determine whether using an opioid in conjunction with low-dose local anesthetics could lessen the adverse effects of the anesthetics.

Spinal anesthesia with levobupivacaine provides potential advantages over bupivacaine with better hemodynamic stability and lesser side effects.

In this context a randomized double blind prospective comparative study was conducted in 130 parturients, who belong to ASA grade I and II posted for elective cesarean sections.

They are randomized into two groups Group BF and Group LF each having 65 patients, to receive hyperbaric bupivacaine 10mg with 25mcg fentanyl and hyperbaric levobupivacaine 10mg with 25mcg fentanyl in Group BF and Group LF respectively.

Then pre op, intra op and post operative parameters are recorded and comparison between two groups was further done using standardized statistical methods.

The mean of regression of dermatome shows significant difference between two group. The mean is higher in group 1 bupivacaine group (177.25 + /-35.691) compared to group 2 levobupivacaine group (151.78 + /-35.016).

The mean of comparison of total duration of sensory block is significantly more in group 1 bupivacaine group (194.6+/-30.543) compared to group 2 levobupivacaine group (166.78+/-31.978). Motor blockade was less in the levobupivacaine group.

Duration of analgesia was significantly more in the bupivacaine group compared to levobupivacaine group. The mean hour in group 1 bupivacaine (196.35+/-29.65) is longer duration compared to group 2 levobupivacaine (170+/-34.425).

The episodes of itching and shivering was significantly lower in levobupivacaine group. There was no incidence of block failure in both the study groups.

# CONCLUSION

Ultimately, it can be concluded that hyperbaric levobupivacaine and hyperbaric bupivacaine both quickly and successfully induce surgical anesthetic for elective cesarean sections without having a negative impact on newborns.

However, combination of fentanyl with levobupivacaine offers shorter sensory and motor block time with better hemodynamic stability and lesser side effects thus minimizing the risk and provides early mobility in parturients after the elective procedure.

Therefore, the combination of levobupivacaine with fentanyl is the preferred alternative for elective cesarean sections.

# REFERENCES

- Bajwa SJ, Kaur J. Clinical profile of levobupivacaine in regional anesthesia: A systematic review. Journal of Anaesthesiology Clinical Pharmacology. 2013 Oct 1;29(4):530-9.
- Goyal A, Shankaranarayan P, Ganapathi P. A randomized clinical study comparing spinal anesthesia with isobaric levobupivacaine with fentanyl and hyperbaric bupivacaine with fentanyl in elective cesarean sections. Anesthesia Essays and Researches. 2015 Jan 1;9(1):57-62.
- 3. Guler G, Cakir G, Ulgey A, Ugur F, Bicer C, Gunes I, Boyaci A. A comparison of spinal anesthesia with levobupivacaine and hyperbaric bupivacaine for cesarean sections: A randomized trial.
- Singh AK, Palaniappan S, Selvaraju K. To Evaluate Efficacy and Safety of Isobaric Levobupivacaine Versus Hyperbaric Bupivacaine in Lower Limb Orthopaedic Surgeries. European Journal of Molecular and Clinical Medicine. 2022 Jan 30;9(3):310-7.
- 5. Kazak Z, Ekmekçi P, Kazbek K. Hyperbaric levobupivacaine in anal surgery: Spinal perianal and spinal saddle blocks. Anaesthesist. 2010.
- Luck JF, Fettes PD, Wildsmith JA. Spinal anaesthesia for elective surgery: a comparison of hyperbaric solutions of racemic bupivacaine, levobupivacaine, and ropivacaine. British journal of anaesthesia. 2008 Nov 1;101(5):705-10.

- Akcaboy EY, Akcaboy ZN, Gogus N. Low dose levobupivacaine
   0.5% with fentanyl in spinal anaesthesia for transurethral resection of prostate surgery. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2011 Jan;16(1):68.
- Cappelleri G, Aldegheri G, Danelli G, Marchetti C, Nuzzi M, Iannandrea G, Casati A. Spinal anesthesia with hyperbaric levobupivacaine and ropivacaine for outpatient knee arthroscopy: a prospective, randomized, double-blind study. Anesthesia & Analgesia. 2005 Jul 1;101(1):77-82.
- Mantouvalou M, Ralli S, Arnaoutoglou H, Tziris G, Papadopoulos G. Spinal anesthesia: comparison of plain ropivacaine, bupivacaine and levobupivacaine for lower abdominal surgery. Acta Anaesthesiologica Belgica. 2008 Jan 1;59(2):65-71.
- 10.Deori AK, Das A, Borgohain D, Bora D, Saikia A, Tiwari PK. A comparative study of spinal anaesthesia with levobupivacaine and hyperbaric bupivacaine for cesarean sections. International Journal of Contemporary Medical Research. 2016;3(7):1902-5.
- 11.Piacherski V, Muzyka L. Comparison of the efficacy of 0.5% isobaric bupivacaine, 0.5% levobupivacaine, and 0.5% hyperbaric bupivacaine for spinal anesthesia in lower limb surgeries. Scientific Reports. 2023 Feb 15;13(1):2736.

- 12.Goel S, Bhardwaj N, Grover VK. Intrathecal fentanyl added to intrathecal bupivacaine for day case surgery: a randomized study. European journal of anaesthesiology. 2003 Apr;20(4):294-7.
- 13.Coppejans HC, Vercauteren MP. Low-dose combined spinal-epidural anesthesia for cesarean delivery: a comparison of three plain local anesthetics. Acta Anaesthesiologica Belgica. 2006 Jan 1;57(1):39-43.
- 14.Gunusen I, Karaman S, Sargin A, Firat V. A randomized comparison of different doses of intrathecal levobupivacaine combined with fentanyl for elective cesarean section: prospective, double-blinded study. Journal of anesthesia. 2011 Apr;25: 205-12.
- 15.Huang YF, Pryor ME, Mather LE, Veering BT. Cardiovascular and central nervous system effects of intravenous levobupivacaine and bupivacaine in sheep. Anesthesia & Analgesia. 1998 Apr 1;86(4):797-804.
- 16.Casimiro C, Rodrigo J, Mendiola MA, Rey F, Barrios A, Gilsanz F. Levobupivacaine plus fentanyl versus racemic bupivacaine plus fentanyl in epidural anaesthesia for lower limb surgery. Minerva anestesiologica. 2008 Apr 18;74(7-8):381-91.
- 17.Butterworth IV JF, Mackey DC, Wasnick JD. Morgan & Mikhail's. Clinical Anesthesiology. 2013.

- 18.Mandabach MG. The early history of spinal anesthesia.InInternational Congress Series 2002 Dec 1 (Vol. 1242, pp. 163-168). Elsevier.
- 19. Whiteside J, Wildsmith T. Spinal anaesthesia. Principles and Practice of Regional Anaesthesia. 2012 Nov 22:124.
- 20.Van Zundert A, Goerig M. August Bier 1861-1949. Regional anesthesia and pain medicine. 2000;25(1):26.
- 21.Salinas FV, Sueda LA, Liu SS. Physiology of spinal anaesthesia and practical suggestions for successful spinal anaesthesia. Best Practice & Research Clinical Anaesthesiology. 2003 Sep 1;17(3):289-303.
- 22.Halaszynski TM, Hartmannsgruber MW. Anatomy and physiology of spinal and epidural anesthesia. InSeminars in Anesthesia, Perioperative Medicine and Pain 1998 Mar 1 (Vol. 17, No. 1, pp. 24-37). WB Saunders.
- 23.Hoehmann CL, Hitscherich K, Cuoco JA. The artery of Adamkiewicz: vascular anatomy, clinical significance and surgical considerations. J Cardiovasc Res 5: 6. doi: 10.4172/2324. 2016 8602:2.
- 24.Melissano G, Bertoglio L, Rinaldi E, Leopardi M, Chiesa R. An anatomical review of spinal cord blood supply. Journal of Cardiovascular Surgery. 2015;56(5):699-706.

- 25.Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Young WL. Miller's anesthesia e-book. Elsevier Health Sciences; 2014 Oct 20.
- 26.Mark JB, Steele SM. Cardiovascular effects of spinal anesthesia. International anesthesiology clinics. 1989 Apr 1;27(1):31-9.
- 27.Butterworth J. Physiology of spinal anesthesia: what are the implications for management. Regional anesthesia and pain medicine. 1998 Jul 1;23(4):370-3.
- 28.Giugliano F, Lippera M, Brugnolo MP, Busca G, Fogliardi A, Carbini MA, Uguccioni S, Roberti L, Sanchioni A. Cervical peridural anesthesia in the surgery of the carotid. First experience. Minerva anestesiologica. 1991 Sep;57(9):460-1.
- 29. Veering BT, Stienstra R. Duration of block: drug, dose, and additives. Regional anesthesia and pain medicine. 1998 Jul 1;23(4):352.
- 30.Pitkänen M, Rosenberg PH. Local anaesthetics and additives for spinal anaesthesia—characteristics and factors influencing the spread and duration of the block. Best Practice & Research Clinical Anaesthesiology. 2003 Sep 1;17(3):305-22.

- 31.Manouchehrian N, Moradi A, Torkashvand L. Comparative study of effect of spinal anesthesia in sitting and lateral positions on the onset time of sensory block and hemodynamic condition in cesarean section: a randomized clinical trial. Anesthesiology and Pain Medicine. 2021 Feb;11(1).
- 32.Mohammadi SS, Piri M, Khajehnasiri A. Comparing three different modified sitting positions for ease of spinal needle insertion in patients undergoing spinal anesthesia. Anesthesiology and Pain Medicine. 2017 Oct;7(5).
- 33.Chang CH, Nam YT, Jeong JY, Choi SI, Lee YW. Comparative Study of Isobaric Bupivacaine Spinal Anesthesia in the Supine and Prone Positions. Korean Journal of Anesthesiology. 2003 May 1;44(5):605-11.
- 34.Foster RH, Markham A. Levobupivacaine: a review of its pharmacology and use as a local anaesthetic. Drugs. 2000 Mar;59(3):551-79.
- 35.Heppolette CA, Brunnen D, Bampoe S, Odor PM. Clinical pharmacokinetics and pharmacodynamics of levobupivacaine. Clinical Pharmacokinetics. 2020 Jun;59(6):715-45.
- 36.Athar M, Ahmed SM, Ali S, Siddiqi OA. Levobupivacaine: A safer alternative. Journal of Current Research in Scientific Medicine. 2016 Jan 1;2(1):3-9.

- 37.Leone S, Di Cianni S, Casati A, Fanelli G. Pharmacology, toxicology, and clinical use of new long acting local anesthetics, ropivacaine and levobupivacaine. Acta Biomed. 2008 Aug 1;79(2):92-105.
- 38.Techanivate A, Urusopone P, Kiatgungwanglia P, Kosawiboonpol R. Intrathecal fentanyl in spinal anesthesia for appendectomy. JOURNAL-MEDICAL ASSOCIATION OF THAILAND. 2004 May 1;87(5):525-30.
- 39.Bogra J, Arora N, Srivastava P. Synergistic effect of intrathecal fentanyl and bupivacaine in spinal anesthesia for cesarean section. BMC anesthesiology. 2005 Dec;5:1-6.
- 40.Lee YY, Muchhal K, Chan CK, Cheung AS. Levobupivacaine and fentanyl for spinal anaesthesia: a randomized trial. European Journal of Anaesthesiology. 2005 Dec;22(12):899-903.
- 41.Bidikar M, Mudakanagoudar MS, Santhosh MC. Comparison of intrathecal levobupivacaine and levobupivacaine plus fentanyl for cesarean section. Anesthesia Essays and Researches. 2017 Apr 1;11(2):495-8.
- 42. Atiénzar MC, Palanca JM, Torres F, Borràs R, Gil S, Esteve I. A randomized comparison of levobupivacaine, bupivacaine and ropivacaine with fentanyl, for labor analgesia. International journal of obstetric anesthesia. 2008 Apr 1;17(2):106-11.

- 43.Bremerich DH, Fetsch N, Zwissler BC, Meininger D, Gogarten W, Byhahn C. Comparison of intrathecal bupivacaine and levobupivacaine combined with opioids for Caesarean section. Current medical research and opinion. 2007 Jan 1;23(12):3047-54.
- 44. Abd-El Wahab EH, Soliman SM, Amen SM, El-Shehdwy SR.
  Comparitive study between levobupivacaine versus bubivacaine in spinal anesthesia for cesarean sections. Tanta Medical Journal. 2018 Jul 1;46(3):232-8.
- 45.Goyal A, Shankaranarayan P, Ganapathi P. A randomized clinical study comparing spinal anesthesia with isobaric levobupivacaine with fentanyl and hyperbaric bupivacaine with fentanyl in elective cesarean sections. Anesthesia Essays and Researches. 2015 Jan 1;9(1):57-62.
- 46.Misirlioglu K, Sivrikaya GU, Hanci A, Yalcinkaya A. Intrathecal low-dose levobupivacaine and bupivacaine combined with fentanyl in a randomised controlled study for caesarean section: blockade characteristics, maternal and neonatal effects. Hippokratia. 2013 Jul;17(3):262.

# **ANNEXURE I**

## **INSTITUTIONAL ETHICAL COMMITTEE**





#### BLDE (DEEMED TO BE UNIVERSITY) Declared as Deemed to be University u/s 3 of UGC Act, 1956 Accredited with 'A' Grade by NAAC (Cycle-2) The Constituent College

SHRI B. M. PATIL MEDICAL COLLEGE, HOSPITAL & RESEARCH CENTRE, VIJAYAPURA 30/8/2022

BLDE (DU)/IEC/ 785/2022-23

#### INSTITUTIONAL ETHICAL CLEARANCE CERTIFICATE

The Ethical Committee of this University met on Friday, 26th August, 2022 at 3.30 p.m. in the Department of Pharmacology scrutinizes the Synopsis of Post Graduate Student of BLDE (DU)'s Shri B.M.Patil Medical College Hospital & Research Centre from ethical clearance point of view. After scrutiny, the following original/ corrected and revised version synopsis of the thesis/ research projects has been accorded ethical clearance.

TITLE: "Comparison of spinal anaesthesia with hyperbaric Levobupivacaine with fentanyl and hyperbaric Bupivacaine with fentanyl in elective cesarean Sections".

NAME OF THE STUDENT/PRINCIPAL INVESTIGATOR: Dr.Sinchana A S

NAME OF THE GUIDE: Dr.Vijaykumar T K, Dept. of Anaesthesiology

Dr.Akram A. Naikwadi Member Secretary IEC, BLDE (DU), MEMBERSECRETARY Institutional Ethics Committee BLDE (Deemed to be University)

Dr. Santoshkumar Jeevangi Chairperson IEC, BLDE (DU), VIJAYAPURA Chairman,

Institutional Ethical Committee, BLDE (Deemed to be University) BLDE (Deemed to be University) BLDE (Deemed to be University) Vijayapura-586103. Karnataka

- Copy of Synopsis/Research Projects
- · Copy of inform consent form
- · Any other relevant document

## ANNEXURE – II

🖌 iThenticate <sup>.</sup>	Similarity Report ID: oid:3618:620612
PAPER NAME	AUTHOR
COMPARISON OF SPINAL ANAESTHESI A WITH HYPERBARIC LEVOBUPIVACAIN E WITH FENTANYL AND HYPERBARIC B UPIVA	Sinchana AS
WORD COUNT	CHARACTER COUNT
9399 Words	55032 Characters
PAGE COUNT	FILE SIZE
76 Pages	1.7MB
SUBMISSION DATE	REPORT DATE
Jun 27, 2024 1:15 PM GMT+5:30	Jun 27, 2024 1:16 PM GMT+5:30
Crossref database	Crossref Posted Content database
Excluded from Similarity Report	
<ul><li>Submitted Works database</li><li>Quoted material</li></ul>	<ul><li>Bibliographic material</li><li>Cited material</li></ul>
Small Matches (Less then 14 words)	
	Summ

#### ANNEXURE – III

#### SAMPLE INFORMED CONSENT FORM:

# B.L.D.E.(DU) SHRI B.M. PATIL MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE, VIJAYAPURA – 586103, KARNATAKA

# TITLE OF THE PROJECT : "COMPARISON OF SPINAL ANAESTHESIA WITH HYPERBARIC LEVOBUPIVACAINE WITH FENTANYL AND HYPERBARIC BUPIVACAINE WITH FENTANYL IN ELECTIVE CESAREAN SECTIONS"

#### PRINCIPAL INVESTIGATOR: Dr. SINCHANA A S

Post graduate, Department of Anaesthesiology <u>sinchusambhrama@gmail.com</u>

P. G. GUIDE

 Dr. Vijaykumar T Kalyanagoppagol Professor,
 Dept of Anaesthesiology, B.L.D. E(DU)
 Shri B.M. Patil Medical College Hospital
 Vijayapura

## PURPOSE OF RESEARCH

# I have been informed that this study is "COMPARISON OF SPINAL ANAESTHESIA WITH HYPERBARIC LEVOBUPIVACAINE WITH FENTANYL AND HYPERBARIC BUPIVACAINE WITH FENTANYL IN ELECTIVE CESAREAN SECTIONS"

I have been well explained in the language I best understand about the procedure, purpose of the study, effects and possible adverse effects of the drugs by the doctor.

I hereby voluntarily give my consent for the participation in the study. I have been explained that I have the right to withdraw the participation from the study at any point I want. And the treatment will not be changed from the standard treatment being followed in the hospital for the denial of participation in the study.

I allow the clinical information related to me to be used for research and academic purpose. I have been explained that my name and identity was concealed throughout the process and the clinical information related to me will not be shared with or given to anyone except \_\_\_\_\_\_ and the concerned clinician.

I have been well explained that I will not be provided with any incentives or compensation in any form for the participation in this study.

I have been explained about the reason for doing this study and selecting me/my ward as a subject for this study. I have also been given free choice for either being included or not in the study.

#### **CONFIDENTIALITY:**

I understand that medical information produced by this study was come a part of this Hospital records and was subjected to the confidentiality and privacy regulation of this hospital. If the data are used for publication in the medical literature or for teaching purpose, no names was used and other identifiers such as photographs and audio or video tapes was used only with my special written permission. I understand that I may see the photograph and videotapes and hear audiotapes before giving this permission.

#### **REQUEST FOR MORE INFORMATION:**

I understand that I may ask more questions about the study at any time. Dr. SINCHANA A S is available to answer my questions or concerns. I understand that I was informed of any significant new findings discovered during the course of this study, which might influence my continued participation.

If during this study, or later, I wish to discuss my participation in or concerns regarding this study with a person not directly involved, I am aware that the social worker of the hospital is available to talk with me.

And that a copy of this consent form was given to me for careful reading.

#### **REFUSAL OR WITHDRAWL OF PARTICIPATION:**

I understand that my participation is voluntary and I may refuse to participate or may withdraw consent and discontinue participation in the study at any time without prejudice to my present or future care at this hospital.

I also understand that Dr. SINCHANA A S will terminate my participation in this study at any time after he has explained the reasons for doing so and has helped arrange for my continued care by my own physician or therapist, if this is appropriate

#### **INJURY STATEMENT:**

I understand that in the unlikely event of injury to me/my ward, resulting directly due to my participation in this study, such injury was reported promptly, then medical treatment would be available to me, but no further compensation was provided.

I understand that by my agreement to participate in this study, I am not waiving any of my legal rights.

Patient's Name:

Age/Sex:

Parents name:

Date:

DR. SINCHANA A S

(Investigator)

Signature of the Parents:

Name:

Relation:

Address:

Witness to above signature

Phone Number:

#### STUDY SUBJECT CONSENT STATEMENT:

I confirm that **Dr. SINCHANA A S** has explained to me the purpose of this research, the study procedure that I will undergo and the possible discomforts and benefits that I may experience, in my own language.

I have been explained all the above in detail in my own language and I understand the same. Therefore, I agree to give my consent to participate as a subject in this research project.

(Patient)

Date

(Witness to above signature)

Date

#### **ANNEXURE IV**

#### PROFORMA

## STUDY: COMPARISON OF SPINAL ANAESTHESIA WITH HYPERBARIC LEVOBUPIVACAINE AND HYPERBARIC BUPIVACAINE WITH FENTANYL IN ELECTIVE CESAREAN SECTION.

Patient Detail	S		IP NO		DATE
Name		Age	sex	weight	
Diagnosis					
Surgical proce	edure				
Past History					
General physi	cal examination:				
Pallor	icterus	С	yanosis		
clubbing	lymphadenopathy	ede	ema		
Mallampatti C	Grade:				
Vital paramet	ers:				
Pulse		blood pr	ressure		
respiratory rat	te	temperatu	ire		
SYSTEMIC I	EXAMINATION				
CVS		CNS			
RS		PA			
INVESTIGA	TIONS				
HB	TC	PLATELET			
HIV	HBSAG	HCV		ASA GRA	DE

#### PARAMETERS TO BE OBSREVERD: VITALS MONITORING

parameters	Group LF/Group BF Levo/bupivacaine group	TIME	PR	BP	MAP	SPO2
SENSORY BLOCK		2MIN				
The onset of sensory		4MIN				
block		6MIN				
Time to reach T10		8MIN				
Time to reach T4		10MIN				
Time of regression of		12MIN				
dermatome		14MIN				
The total duration of		16MIN				
sensory block		18MIN				
MOTOR BLOCK		20MIN				
The onset of motor block		22MIN				
Time to reach maximum		24MIN				
level		26MIN				
Duration of analgesia		28MIN				
Side effects		30MIN				
hypotension		45MIN				
bradycardia		1HR				
Nausea, vomiting		1.30HR				
headache		2 <sup>nd</sup> HR				
itching		2.30HR				
shivering		3 <sup>rd</sup> HR				
APGAR SCORE		4 <sup>th</sup> HR				
1MIN		6 <sup>th</sup> HR				
		12 <sup>th</sup> HR				
5MIN		24HR				

#### **BIO-DATA**

Guide Name:	Dr. Vijaykumar T Kalyanappagol
Date of Birth:	08/09/1964
Education :	M.B.B.S. from M R Medical College Kalaburgi
	M D from Shri B.M.P.A.T.I.L. Medical college vijayapur
	D A from J.N. Medical College Belgaum
Designation :	Professor in Anesthesiology
Teaching:	Total work experience 30 years
	P.G. teaching for 22years
	P.G. guide 13 years
Address:	Plot No.43, Basaveshwara Nagar, Opposite BLDE Hospital,
	Ashram Road, Vijayapura.

#### INVESTIGATOR

Name	:	Dr. Sinchana. A. S
Qualification:		M.B.B.S.
		Vijayanagar institute of medical sciences, Bellary
Registration No.	:	134744
Address	:	SHREESHA, gundibail, Doddanagudde road,
		shivalli village
		UDUPI

# MASTER CHART – BUPIVACAINE GROUP

|              | ¥   | N  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  |   |
|--------------|---|--|--|---
--
--
--
--
--
--
--
---
--
--
--
---
--
--
--
---
--
--
--
---
--
--
---|--
---|---|---|---
--
--
---|---
--
--
---|--
--
--
--
--|---
---
--
---|--|--
---
---
--
--	---
	APGA
   
   
  | 9  
   
   
   
  | •••  
   
   
  | 9  
   
   
  | 6                                  
   
   
   
  | 6  
   
   
  | 9  | 9   | ~   | ~   | ~   | 9   
   
   | 9   
   | 6   
   
   | ~  | 6  
   
   | 6   
  | ~  
  | 9   | 9  
  | 9  | 6  | 9  
  | 9  
  | 9  
   | ~  | 6   | •••  
  | 6   |
| APGAR        | AT 1  | NIM  | ~~   | ~   | ~   
   
   
  | ~  
   
   
   
  | ٢  
   
   
  | ~  
   
   
  | •••                                
   
   
   
  | ~  
   
   
  | ~  | ~   | ٢   | ٢   | ٢   | ~   
   
   | ~   
   | ~   
   
   | ٢  | •••  
   
   | •••   
  | ٢  
  | ~~  | ~  
  | ~  | ~  | ~  
  | ~  
  | ~  
   | ٢  | •••   | 2  
  | ~   |
|              | HIVERIN   | 9  | ABSENT   | ABSENT  | ABSENT  
   
   
  | ABSENT   
   
   
   
  | RESENT   
   
   
  | ABSENT   
   
   
  | RESENT                             
   
   
   
  | ABSENT   
   
   
  | ABSENT   | ABSENT  | ABSENT  | ABSENT  | RESENT  | ABSENT  
   
   | ABSENT  
   | RESENT  
   
   | ABSENT   | ABSENT   
   
   | RESENT  
  | RESENT   
  | RESENT  | ABSENT   
  | ABSENT   | ABSENT   | ABSENT   
  | ABSENT   
  | ABSENT   
   | ABSENT   | RESENT  | ABSENT   
  | ABSENT  |
|              | S   | BUIH   |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | ABSENT  |
|              | AC  |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  |   |
| Å,           |   | Ŧ  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  | VT PRES  
  |  
   |  |   |  
  | VT PRESENT  |
| NAUSE        | LIMON C   | 9  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   | T ABSEI   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  | T PRESE  
  | T ABSEI  
   | T PRESE  | T PRESE   | T PRESE  
  | T ABSENT  |
|              |   |  | T ABSEN  | r Absen   |   
   
   
  | T PRESEN   
   
   
   
  | T ABSEN  
   
   
  | T ABSEN  
   
   
  | T ABSEN                            
   
   
   
  |  
   
   
  | T ABSEN  | T ABSEN   | T PRESEN  | T ABSEN   | <b>ABSEN</b>  | r Preser  
   
   | r Absen   
   | r Absen   
   
   | T ABSEN  | T ABSEN  
   
   | r Absen   
  |  
  | T ABSEN   |  
  | T ABSEN  | r Absen  | <b>ABSEN</b>   
  | <b>ABSEN</b>   
  | T ABSEN  
   | <b>ABSEN</b>   | T PRESEN  | r Absen  
  | r absent  |
|              |   |  | PRESEN   | ABSEN   | ABSEN   
   
   
  | PRESEN   
   
   
   
  | PRESEN   
   
   
  | PRESEN   
   
   
  | PRESEN                             
   
   
   
  | ABSEN  
   
   
  | PRESEN   | PRESEN  | PRESEN  | PRESEN  | ABSEN   | ABSEN   
   
   | ABSEN   
   | ABSEN   
   
   | PRESEN   | PRESEN   
   
   | ABSEN   
  | ABSEN  
  | PRESEN  | ABSEN  
  | PRESEN   | ABSEN  | ABSEN  
  | ABSEN  
  | PRESEN   
   | ABSEN  | PRESEN  | ABSEN  
  | ABSENT  |
|              |   |  | 8  | 92  | 8   
   
   
  | 88   
   
   
   
  | 8  
   
   
  | 56   
   
   
  | 7                                  
   
   
   
  | 8  
   
   
  | 41   | 76  | 69  | 2   | 2   | 8   
   
   | 92  
   | 8   
   
   | 22   | 2  
   
   | 7   
  | 2  
  | 99  | 8  
  | 2  | 92   | 94   
  | 82   
  | 64   
   | 82   | 57  | 62   
  | 2   |
|              |   |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | 118   |
|              |   |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | 4 83  |
|              |   |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | 82 124  |
|              |   |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | 122 8   |
| 8            |   |  |  |   | 1   
   
   
  | 3  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   | 1   
   
   | 76 1  
   | 1   
   
   |  |  
   
   |   
  |  
  |   |  
  | 1  |  | 1  
  | 1  
  |  
   |  |   |  
  | 5   |
|              |   |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | 11  |
| 5            |   |  | 09   | 8   | 26  
   
   
  | 8  
   
   
   
  | 88   
   
   
  | 22   
   
   
  | 5                                  
   
   
   
  | 23   
   
   
  | 53   | 63  | 53  | 8   | 99  | 22  
   
   | 1   
   | 53  
   
   | 20   | 99   
   
   | 65  
  | 53   
  | 82  | 8  
  | 38   | 8  | 4  
  | R  
  | 53   
   | 88   | 69  | 36   
  | 2   |
| 5            |   |  | 5  |   | 132   
   
   
  | 5  
   
   
   
  | 122  
   
   
  | 116  
   
   
  | =                                  
   
   
   
  | 6  
   
   
  | 122  | 114   | 101   | 113   | 형   | 101   
   
   | 125   
   | 125   
   
   | 101  | 8  
   
   | 88  
  | 8  
  | <u>10</u>   | 61   
  | 헐  | 됟  | 173  
  | 116  
  | 8  
   | 113  | 11  | 17   
  | 53  |
| 음            |   |  | R  | 8   | 99  
   
   
  | R  
   
   
   
  | 88   
   
   
  | 88   
   
   
  | 99                                 
   
   
   
  | 22   
   
   
  | 53   | 2   | 7   | 7   | 2   | 8   
   
   | 2   
   | R   
   
   | 6  | 8  
   
   | 92  
  | 2  
  | 8   | 53   
  | R  | 8  | 2  
  | 62   
  | 92   
   | 62   | 53  | 62   
  | 8   |
| 엵            | MIN   | ß  | 120  | 130   | 121   
   
   
  | <u>10</u>  
   
   
   
  | 116  
   
   
  | 112  
   
   
  | 117                                
   
   
   
  | 61   
   
   
  | =  | 122   | Ξ   | <u>11</u>   | 108   | 9   
   
   | 124   
   | 126   
   
   | <u>11</u>  | 8  
   
   | 127   
  | 129  
  | 8   | 120  
  | 8  | 53   | 121  
  | 114  
  | 127  
   | 102  | 102   | <u>18</u>  
  | 120   |
| ŝ            | MIN   | 留  | 09   | 8   | 88  
   
   
  | 89   
   
   
   
  | 2  
   
   
  | R  
   
   
  | 88                                 
   
   
   
  | ۴  
   
   
  | 69   | 89  | 7   | 89  | 92  | 2   
   
   | 2   
   | ۴   
   
   | 09   | \$   
   
   | 99  
  | 8  
  | 47  | 2  
  | 92   | 8  | 2  
  | 63   
  | 99   
   | 22   | 69  | ۴  
  | 59  |
| ŝ            | M   |  | 112  | 140   | 120   
   
   
  | %  
   
   
   
  | 129  
   
   
  | <u>10</u>  
   
   
  | 11                                 
   
   
   
  | 122  
   
   
  | 123  | 121   | <u>1</u>  | 8   | 120   | 130   
   
   | 122   
   | 121   
   
   | 110  | 124  
   
   | 113   
  | 135  
  | 8   | 126  
  | 120  | 140  | 122  
  | 115  
  | 113  
   | 92   | 117   | 122  
  | 111   |
| 4            |   |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | 8   |
|              | N   |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | 55 130  |
|              |   |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   |   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | 100 5   |
| 2            |   |  |  |   |   
   
   
  |  
   
   
   
  |  
   
   
  |  
   
   
  |                                    
   
   
   
  |  
   
   
  |  |   |   |   |   |   
   
   |   
   | 4 1   
   
   |  |  
   
   |   
  |  
  |   |  
  |  |  |  
  |  
  |  
   |  |   |  
  | 55 1  |
| 5            | NIN   |  | 8  | 8   | 5   
   
   
  | 130  
   
   
   
  | 141  
   
   
  | <u>10</u>  
   
   
  | 8                                  
   
   
   
  | 12   
   
   
  | 8  | 96  | 8   | 106   | 8   |   
   
   | 133   
   | 126   
   
   | 130  | 132  
   
   |   
  | 134  
  |   | 121  
  | 8  | 13   | 134  
  | 53   
  | Ξ  
   | 118  | 106   |  
  | 8   |
|              |   | B  | 5  | 25  | 8   
   
   
  | 똶  
   
   
   
  | 8  
   
   
  | R  
   
   
  | 53                                 
   
   
   
  | 83   
   
   
  | 53   | 64  | 2   | К   | 2   | 9   
   
   | 8   
   | 8   
   
   | 8  | 컶  
   
   | 8   
  | 22   
  | 92  | 8  
  | R  | 25   | 96   
  | 92   
  | 8  
   | 83   | 53  | 53   
  | 99  |
|              |   | ß  | 100  | 142   | 136   
   
   
  | 138  
   
   
   
  | 138  
   
   
  | 110  
   
   
  | 11                                 
   
   
   
  | 134  
   
   
  | 110  | 61  | 130   | 124   | 110   | 11  
   
   | 134   
   | 128   
   
   | 140  | 130  
   
   | 120   
  | 124  
  | 124   | 128  
  | 11   | 142  | 136  
  | 123  
  | 120  
   | 128  | 109   | 113  
  | 115   |
| BIO          | 8   | PRES   | 8  | 98  | 2   
   
   
  | 82   
   
   
   
  | 110  
   
   
  | 8  
   
   
  | 8                                  
   
   
   
  | 2  
   
   
  | 8  | 2   | 8   | 2   | 8   | 8   
   
   | 8   
   | 8   
   
   | 8  | 8  
   
   | ₽   
  | 8  
  | 8   | 8  
  | 8  | 8  | 8  
  | 8  
  | 2  
   | 8  | R   | R  
  | 8   |
| 80           | 8   |  | 120  | 148   | 14  
   
   
  | 130  
   
   
   
  | 142  
   
   
  | 120  
   
   
  | 110                                
   
   
   
  | 130  
   
   
  | 120  | 110   | 130   | 110   | 120   | 120   
   
   | 120   
   | 120   
   
   | 120  | 120  
   
   | 136   
  | 120  
  | 110   | 120  
  | 120  | 5  | 140  
  | 130  
  | 110  
   | 120  | 110   | 11   
  | 130   |
| NOF          | ANA   | GESI   | 180  | 8   | 8   
   
   
  | 220  
   
   
   
  | 165  
   
   
  | 150  
   
   
  | 180                                
   
   
   
  | 8  
   
   
  | 81   | 81  | 210   | 240   | 240   | 240   
   
   | 8   
   | 8   
   
   | 240  | 240  
   
   | 210   
  | 81   
  | 180   | 8  
  | 5  | 8  | 180  
  | 240  
  | 180  
   | 81   | 240   | 160  
  | 186   |
| EAC          | Ŧ   | <b>NAXI</b>  | 2  | 5   | 8   
   
   
  |  
   
   
   
  | =  
   
   
  | 2  
   
   
  | 9                                  
   
   
   
  | 4  
   
   
  | ŝ  | ÷   | 2   | 2.5   | ŝ   | ŝ   
   
   | 5   
   | ŝ   
   
   | ŝ  | ŝ  
   
   | 2   
  | ŝ  
  | ŝ   | ÷  
  | ÷  | 5  | 5  
  | 2  
  | 7  
   | 7  | 2.3   | 7  
  |   |
| <b>E</b>     | ъ   | NOT N  |  | 4   | 4   
   
   
  | 0.8  
   
   
   
  |  
   
   
  | 2  
   
   
  |                                    
   
   
   
  | m  
   
   
  | 2  |   | 0.8   | 2   |   | 2   
   
   | 4   
   |   
   
   | 2  | 2  
   
   | 0.8   
  | 2  
  | 2   |  
  |  | 4  | 4  
  | 13   
  |  
   |  | 2   |  
  | 0.8   |
| <b>TION</b>  | ы   | SENSO  | 180  | 150   | 180   
   
   
  | 180  
   
   
   
  | 180  
   
   
  | 150  
   
   
  | 180                                
   
   
   
  | 180  
   
   
  | 210  | 180   | 220   | 180   | 210   | 230   
   
   | 150   
   | 240   
   
   | 210  | 240  
   
   | 210   
  | 180  
  | 180   | 240  
  | 210  | 150  | 150  
  | 240  
  | 180  
   | 195  | 215   | 140  
  | 200   |
|              | SION  | ų  | 195  | 120   | 170   
   
   
  | 120  
   
   
   
  | 165  
   
   
  | 120  
   
   
  | 150                                
   
   
   
  | 120  
   
   
  | 180  | 180   | 200   | 170   | 240   | 240   
   
   | 120   
   | 210   
   
   | 180  | 180  
   
   | 180   
  | 150  
  | 190   | 210  
  | 240  | 120  | 120  
  | 210  
  | 170  
   | 180  | 180   | 120  
  | 170   |
|              | Ŧ   | T4(MI  | 0  | 20  | •   
   
   
  | 5  
   
   
   
  | 2  
   
   
  | •  
   
   
  | 0                                  
   
   
   
  | •  
   
   
  | 0  | •   | •   | 0   | 0   | 0   
   
   | 0   
   | •   
   
   | •  | •  
   
   | •   
  | 0  
  | •   | •  
  | 0  | 0  | •  
  | •  
  | •  
   | 0  | 0   | •  
  | •   |
| REACH        | T10(MI  |  | 0.8  | 5   | ~   
   
   
  |  
   
   
   
  | 0.8  
   
   
  | 11   
   
   
  | 5                                  
   
   
   
  | ŝ  
   
   
  | 2  | 2   | 2   | 2   | 2   | ŝ   
   
   | m   
   | 2   
   
   | 2.1  | 2  
   
   | 1.2   
  |  
  | ŝ   | 2  
  | 2  | ŝ  | ŝ  
  |  
  | 1.5  
   | 1.5  | 2   | 1.15   
  | 2   |
| <b>SENSO</b> | R   |  | 0.6  | 2   |   
   
   
  | 0.6  
   
   
   
  |  
   
   
  |  
   
   
  | 2                                  
   
   
   
  | 2  
   
   
  |  | 2   |   |   |   | 2   
   
   | 2   
   |   
   
   | 2  | 1.5  
   
   |   
  | 0.8  
  | 2   |  
  |  | 2  | 2  
  | 0.3  
  | 0.8  
   |  |   | 0.8  
  |   |
|              |   | AGE  | 22   | 38  | 20  
   
   
  | A 28   
   
   
   
  | 8  
   
   
  | 22   
   
   
  | V 22                               
   
   
   
  | 31   
   
   
  | 20   | 27  | 1 29  | 33  | 33  | 1 27  
   
   | 22  
   | 8   
   
   | 22   | 33   
   
   | J 22  
  | 1 21   
  | 23  | 27   
  | 22   | 24   | 21   
  | 24   
  | 20   
   | A 27   | L 26  | 33   
  | 33  |
|              |   | NAME   | POOJA  | KAVITHA   | LAKSHMI   
   
   
  | OORNIM   
   
   
   
  | HARADA   
   
   
  | SAVITHA  
   
   
  | KATHAV                             
   
   
   
  | ZEENAT   
   
   
  | LAKSHMI  | KAVERI  | ZRA BEGU  | SHILPA  | RENUKA  | NNAWW   
   
   | POOJA   
   | LAKSHMI   
   
   | KAVERI   | SUREKHA  
   
   | <b>NGEETH</b>   
  | AHADEV   
  | SUCHITRA  | BHARATI  
  | KAVERI   | KAVITHA  | SUFIAN   
  | PUSHPA   
  | BHARATI  
   | BHILASH/   | AKUNTAI   | FIRDOZ   
  | SHRUTHI   |
| ≥            | BB  | 85   |  | 2   | 3   
   
   
  | 4 PC   
   
   
   
  | 5 S  
   
   
  | 9  
   
   
  | 7 U                                
   
   
   
  | ~  
   
   
  | 9  | 9   | 11 🗸  | 12  | 13  | 14 .A   
   
   | 5   
   | 16 L  
   
   | 17   | 18   
   
   | 19 34   
  | 20 M   
  | 21 S  | 22 E   
  | 33   | 24 K   | 25   
  | 26   
  | 27   
   | 28 A.  | 29 H.   | 8  
  | 31  |
|              | ET REAC NOF BLO BLO 1 2 2 3 3 4 4 5 5 10 10 15 15 20 20 30 30 45 45 HOU 1 MAUSEA, | REAC REGRES         TON         ET         REAC NOF         BLO         1         2         2         3         3         4         4         5         10         15         20         20         30         45         45         HOU         I         NAUSEA,           H         SION         OF         H         AMA         OD         DMIN         MIN         M | Series         Reach         Rea         Reach         Reach | Result         Restort         Restort         Resto | Resol         Resch         Resch <th< td=""><td>Reso         Res         Res<td>Find         Find         <th< td=""><td>Find         Find         <th< td=""><td>Find         Find         <th< td=""><td>Find         Find         <th< td=""><td>Service         Reack (red rec rec rec rec rec rec rec rec rec rec</td><td>SEND         REACH         REACH         REACH         Noit         F         REACH         REACH         REACH         Noit         F         Nout         F         No         No</td><td>Service         Rescr         Tiol         F         Rescr         Tiol         F</td><td>Served         Redict         Redict&lt;</td><td>Serve         Reach         Tiol         F         Reach         F         A         2         3         4         5         10         1         2         3         4         5         10         10         NUMBE         NUMBE</td><td>Server         Server         Nor         Fail         Nor         Fail         Nor         Fail         Nor         <t< td=""><td>Series         Series         Series&lt;</td><td>Field         Field         <th< td=""><td>Were         Marce         Marce</td><td>Norw         Norw         <th< td=""><td>WINK         MECK         <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<></td></th<></td></th<></td></t<></td></th<></td></th<></td></th<></td></th<></td></td></th<> | Reso         Res         Res <td>Find         Find         <th< td=""><td>Find         Find         <th< td=""><td>Find         Find         <th< td=""><td>Find         Find         <th< td=""><td>Service         Reack (red rec rec rec rec rec rec rec rec rec rec</td><td>SEND         REACH         REACH         REACH         Noit         F         REACH         REACH         REACH         Noit         F         Nout         F         No         No</td><td>Service         Rescr         Tiol         F         Rescr         Tiol         F</td><td>Served         Redict         Redict&lt;</td><td>Serve         Reach         Tiol         F         Reach         F         A         2         3         4         5         10         1         2         3         4         5         10         10         NUMBE         NUMBE</td><td>Server         Server         Nor         Fail         Nor         Fail         Nor         Fail         Nor         <t< td=""><td>Series         Series         Series&lt;</td><td>Field         Field         <th< td=""><td>Were         Marce         Marce</td><td>Norw         Norw         <th< td=""><td>WINK         MECK         <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<></td></th<></td></th<></td></t<></td></th<></td></th<></td></th<></td></th<></td> | Find         Find <th< td=""><td>Find         Find         <th< td=""><td>Find         Find         <th< td=""><td>Find         Find         <th< td=""><td>Service         Reack (red rec rec rec rec rec rec rec rec rec rec</td><td>SEND         REACH         REACH         REACH         Noit         F         REACH         REACH         REACH         Noit         F         Nout         F         No         No</td><td>Service         Rescr         Tiol         F         Rescr         Tiol         F</td><td>Served         Redict         Redict&lt;</td><td>Serve         Reach         Tiol         F         Reach         F         A         2         3         4         5         10         1         2         3         4         5         10         10         NUMBE         NUMBE</td><td>Server         Server         Nor         Fail         Nor         Fail         Nor         Fail         Nor         <t< td=""><td>Series         Series         Series&lt;</td><td>Field         Field         <th< td=""><td>Were         Marce         Marce</td><td>Norw         Norw         <th< td=""><td>WINK         MECK         <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<></td></th<></td></th<></td></t<></td></th<></td></th<></td></th<></td></th<> | Find         Find <th< td=""><td>Find         Find         <th< td=""><td>Find         Find         <th< td=""><td>Service         Reack (red rec rec rec rec rec rec rec rec rec rec</td><td>SEND         REACH         REACH         REACH         Noit         F         REACH         REACH         REACH         Noit         F         Nout         F         No         No</td><td>Service         Rescr         Tiol         F         Rescr         Tiol         F</td><td>Served         Redict         Redict&lt;</td><td>Serve         Reach         Tiol         F         Reach         F         A         2         3         4         5         10         1         2         3         4         5         10         10         NUMBE         NUMBE</td><td>Server         Server         Nor         Fail         Nor         Fail         Nor         Fail         Nor         <t< td=""><td>Series         Series         Series&lt;</td><td>Field         Field         <th< td=""><td>Were         Marce         Marce</td><td>Norw         Norw         <th< td=""><td>WINK         MECK         <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<></td></th<></td></th<></td></t<></td></th<></td></th<></td></th<> | Find         Find <th< td=""><td>Find         Find         <th< td=""><td>Service         Reack (red rec rec rec rec rec rec rec rec rec rec</td><td>SEND         REACH         REACH         REACH         Noit         F         REACH         REACH         REACH         Noit         F         Nout         F         No         No</td><td>Service         Rescr         Tiol         F         Rescr         Tiol         F</td><td>Served         Redict         Redict&lt;</td><td>Serve         Reach         Tiol         F         Reach         F         A         2         3         4         5         10         1         2         3         4         5         10         10         NUMBE         NUMBE</td><td>Server         Server         Nor         Fail         Nor         Fail         Nor         Fail         Nor         <t< td=""><td>Series         Series         Series&lt;</td><td>Field         Field         <th< td=""><td>Were         Marce         Marce</td><td>Norw         Norw         <th< td=""><td>WINK         MECK         <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<></td></th<></td></th<></td></t<></td></th<></td></th<> | Find         Find <th< td=""><td>Service         Reack (red rec rec rec rec rec rec rec rec rec rec</td><td>SEND         REACH         REACH         REACH         Noit         F         REACH         REACH         REACH         Noit         F         Nout         F         No         No</td><td>Service         Rescr         Tiol         F         Rescr         Tiol         F</td><td>Served         Redict         Redict&lt;</td><td>Serve         Reach         Tiol         F         Reach         F         A         2         3         4         5         10         1         2         3         4         5         10         10         NUMBE         NUMBE</td><td>Server         Server         Nor         Fail         Nor         Fail         Nor         Fail         Nor         <t< td=""><td>Series         Series         Series&lt;</td><td>Field         Field         <th< td=""><td>Were         Marce         Marce</td><td>Norw         Norw         <th< td=""><td>WINK         MECK         <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<></td></th<></td></th<></td></t<></td></th<> | Service         Reack (red rec | SEND         REACH         REACH         REACH         Noit         F         REACH         REACH         REACH         Noit         F         Nout         F         No         No | Service         Rescr         Tiol         F         Rescr         Tiol         F | Served         Redict         Redict< | Serve         Reach         Tiol         F         Reach         F         A         2         3         4         5         10         1         2         3         4         5         10         10         NUMBE         NUMBE | Server         Server         Nor         Fail         Nor         Fail         Nor         Fail         Nor         Nor <t< td=""><td>Series         Series         Series&lt;</td><td>Field         Field         <th< td=""><td>Were         Marce         Marce</td><td>Norw         Norw         <th< td=""><td>WINK         MECK         <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<></td></th<></td></th<></td></t<> | Series         Series< | Field         Field <th< td=""><td>Were         Marce         Marce</td><td>Norw         Norw         <th< td=""><td>WINK         MECK         <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<></td></th<></td></th<> | Were         Marce         Marce | Norw         Norw <th< td=""><td>WINK         MECK         <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<></td></th<> | WINK         MECK         MECK <th< td=""><td>Sector         Biolog         Color         &lt;</td><td>Strong list for the field list for the list of the list</td><td>Find         Find         <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<></td></th<> | Sector         Biolog         Color         < | Strong list for the field list for the list of the list | Find         Find <th< td=""><td>Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in</td><td>Serve Rocki record         Rocki r</td><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<></td></th<> | Filter         Image: inclusion inclusine inclusine inclusion inclusion inclusion inclusina inclusica in | Serve Rocki record         Rocki r | Note         Note <th< td=""><td>Note         Note         <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<></td></th<> | Note         Note <th< td=""><td>Mode         Mode         1         1         3         4         4         1<!--</td--><td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td></td></th<> | Mode         Mode         1         1         3         4         4         1 </td <td>Note         Note         <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<></td> | Note         Note <th< td=""><td>Monto         I         Monto         I         Monto         Monto<!--</td--><td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td></td></th<> | Monto         I         Monto         I         Monto         Monto </td <td>Note         Note         <th< td=""><td>Note         Note         <th< td=""></th<></td></th<></td> | Note         Note <th< td=""><td>Note         Note         <th< td=""></th<></td></th<> | Note         Note <th< td=""></th<> |

6	~	6	6	6	6	7	~	6	~	~	~	6	~	~	~	6	~	6	6	6	~	~	6	~	~	~	6	6	6	6	~	~	9
~	~	~	~	~	~	9	~	~	2	2	٢	2	2	٢	٢	~	2	~	~	~	٢	2	~	~	~	~	~	~	~	~	2	~	~
ABSENT	PRESENT	PRESENT	PRESENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	PRESENT	PRESENT	ABSENT	ABSENT	PRESENT	PRESENT	ABSENT	ABSENT	PRESENT	ABSENT	PRESENT	ABSENT	PRESENT	PRESENT	PRESENT	ABSENT	ABSENT	ABSENT	PRESENT	PRESENT	ABSENT
PRESENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	PRESENT	PRESENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	PRESENT
ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	PRESENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	PRESENT	ABSENT	PRESENT	ABSENT	ABSENT
ABSENT	ABSENT A	PRESENT A	PRESENT A	ABSENT	ABSENT	PRESENT A	ABSENT	PRESENT A	ABSENT A	PRESENT A		ABSENT A		ABSENT	ABSENT	ABSENT	ABSENT		ABSENT A	ABSENT	PRESENT PI	PRESENT PI	ABSENT A	PRESENT A	ABSENT A	PRESENT PI	ABSENT	ABSENT	ABSENT PI	PRESENT A		PRESENT A	ABSENT A
	ABSENT AB	PRESENT PRE	ABSENT PRE	ABSENT AB	ABSENT AB	ABSENT PRE	ABSENT AB	ABSENT PRE	ABSENT AB	ABSENT PRE	ABSENT PRESENT	ABSENT AB	PRESENT PRESENT PRESENT		ABSENT AB	ABSENT AB	SENT AB	PRESENT PRESENT PRESENT	ABSENT AB	ABSENT AB	ABSENT PRE	SENT PRE		ABSENT PRE	ABSENT AB	ABSENT PRE	ABSENT AB	ABSENT AB		ENT PRE	PRESENT PRESENT PRESENT	ENT PRE	
PRESENT ABSENT	INT ABS	ENT PRE		INT ABS	INT ABS	INT ABS	ENT ABS	INT ABS		INT ABS	INT ABS	INT ABS	ENT PRE	PRESENT ABSENT	INT ABS	INT ABS	ABSENT PRESENT	ENT PRE	INT ABS		INT ABS	PRESENT PRESENT	PRESENT ABSENT	INT ABS	INT ABS	ENT ABS	INT ABS	INT ABS	PRESENT ABSENT	ABSENT ABSENT	ENT PRE	PRESENT ABSENT	PRESENT PRESENT
	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	_		ABSENT	ABSENT			ABSENT	ABSENT	ABSENT			ABSENT	ABSENT	PRESENT	ABSENT	ABSENT					
22	22	2	8	5	8	33	22	2	22	8	8	2	8	74	74	88	82	7	92	82	8	22	99	8	22	8	74	8	99	7	2	62	88
124	120	11	131	122	120	114	123	118	132	122	121	126	128	126	109	110	126	113	124	132	130	121	118	128	128	8	124	130	=	124	118	106	120
22	22	2	22	F	≈	22	99	8	81	82	82	8	8	62	62	2	8	23	22	86	101	22	2	92	92	5	22	8	5	99	8	62	2
128	116	130	130	137	<del>11</del>	112	113	120	125	124	118	128	123	123	114	108	122	120	122	131	138	120	121	132	120	11	128	128	136	124	120	9	120
92	69	83	ଛ	ଛ	8	61	99	81	9/	81	72	8	8	72	88	62	8	74	ଛ	82	100	22	ଛ	<u>6</u>	82	5	ଛ	74	92	5	8	62	2
132	113	117	126	14	120	105	120	122	123	127	123	131	120	121	125	103	131	119	120	130	146	118	122	137	118	8	130	121	130	114	<u>119</u>	102	128
69	7	왕	29	26	5	52	46	8	88	22	29	8	82	61	99	8	8	8	4	R	102	8	23	5	22	20	R	5	5	29	53	5	8
126	13	8	87	E	125	11	102	117	130	102	125	121	<b>21</b>	<u>10</u>	<u>10</u>	101	131	E	8	120	147	116	<b>2</b>	ŝ	83	171	8	8	8	87	8	8	8
2	38	4	5	88	2	99	99	19	15	4	8	8	8	8	69	6	5	<b>\$</b>	2	88	ŝ	88	21	2	2	98	2	R	8	92	8	62	85
128	121	ŝ	8	139	124	120	53	8	132	11	126	112	126	≣	127	106	121	≈	116	118	142	114	8	112	51	E	126	8	8	124	8	8	51
2	74 1	22	59	96	1	53	20	5	8	1	1	8	2	62 1	73	61 1	8	4	82	62 1	1	2	99	7	8	33	7	8	39	8	52	8	2
136	8	5	124	<u></u>	121	125	5	8	130	128	128	61	121	101	125	105	3	8	61	102	130	100	105	132	126	100	128	8	8	8	96	6	100
78 1	71	8	66 1	89	1	1	67 1	\$	88	79 1	89 1	8	8	60 1	73 1	74 1	8	22	5	50 1	99	60	61	72 1	72 1	42 1	5	60	47	78	4	61 1	54
8	124	10	521	149	12	126	11	124	129	126	179	120	11	8	671	61	12	5	126	32	141	88	8	8	53	\$8	136	<b>%</b>	53	126	98	8	98
74	2	53	53	8	88	8	99	25	98	F	22	8	99	33	5	33	8	99	22	ŝ	25	62	3	\$	82	**	22	22	52	92	36	99	17
141	118	8	124	139	123	121	11	126	124	125	138	5	<u>10</u>	5	128	103	11	102	121	8	128	32	%	124	129	8	132	8	8	122	88	8	<b>1</b> 2
F	2	62	19	88	8	\$	5	7	25	5	23	99	99	53	74	64	99	21	\$	09	≋	8	43	⊗	29	47	⊨	53	\$	R	32	99	99
	129	102	13	143	128	115	6	131	129	130	123	8	92	8	110	101	8	8	53	100	134	\$	8	120	138	6	14	<u>1</u>	8	116	2	16	25
8	92	21	92	92	5	52	99	℅	컶	62	82	R	52	09	8	53	R	62	5	R	8	99	\$	R	23	۶	ଛ	99	R	92	\$	46	98
131	136	101	125	131	133	121	8	132	128	121	127	110	≋	102	8	103	110	102	121	118	135	8	8	112	123	Ħ	131	102	106	123	8	8	11
52	8	[9	22	8	8	74	2	\$	8	33	F	82	64	63	52	74	82	57	7	82	8	2	52	99	82	≈	62	8	76	8	20	5	82
126	139	116	124	139	134	126	130	130	120	124	126	120	8	108	120	110	120	<u>1</u>	126	128	125	<u>6</u>	<b>10</b>	11	127	120	126	11	124	130	8	8	124
8	8	2	8	2	8	2	12	8	8	92	6	<u>10</u>	09	2	6	2	2	8	8	8	2	2	12	8	≈	2	8	8	8	<u>11</u>	2	ŝ	8
120	15	<u>11</u>	130	120	130	110	112	14	130	150	140	140	120	112	140	110	130	130	120	120	120	110	112	120	130	<u>8</u>	120	<u>6</u>	130	140	110	Ξ	130
<b>Z</b> 40	81	2	81	226	81	180	<b>2</b> 40	210	240	81	180	186	250	220	165	120	13	21	61	180	220	<b>5</b> 40	230	81	R	8	22	53	81	81	<b>5</b> 40	81	醫
2	1.2	15	7		4	~	~	~	1.15	13				~	2	9		5	~	15		4	13	~		7	7	9	7	5	5	~	
	0.8			0.5	m		2	2	0.3		0.2	0.8	0.5		0.8	ŝ	0.6				0.5		0.5		0.5	0.8	0.8	2		2		m	0.5
230	61	81	195	235	180	230	220	195	240	180	180	61	215	180	130	6	170	174	230	195	180	210	210	215	210	220	230	165	220	180	230	61	220
225	175	5	220	230	120	210	17	170	192	190	160	175	228	250	160	<u>10</u>	155	140	220	190	150	225	195	185	166	170	225	170	180	165	200	<sup>18</sup>	180
2	0	0	0	0	0	5	0	0	0	2	0	0	2	0	0	0	0	0	0	0	0	<del>~</del>	0	0	0	0	2	0	2	0	9	0	0
	2			2	2	2	2.5				2	2		1.2		5	2		2	1.3					2	0.8		ŝ		4	1.45	2.3	13
0.5		03	0:3	2			2	0.8	0.8	0.8			0.8	0.5	0.5	2		0.5		0.5	0.8	0.5	0.8	0.5	0.8	03	0.5	2	0.8	ŝ		2	
33	8	24	3	33	1 19	24	71	83	8	27	53	34	31	67	24	33	82	32	8	22	33	1 21	27	23	26	36	26	24	61	21	31	8	22
32 JAYASHREE	33 SANGEETA	SAVITRI	30 HAKUNTAL	36 SAVITHA	<b>37 HAGYASHRI</b>	PRIYANKA	KAVERI	40 IAJESHWAF	UJWALA	42 Kaushalya	DIVYA	PRIYA	RATNA	46 SANGAMM	REKHA	48 IJAYALSHN	49 KUCHATAI	50 KAVITHA	51 HARSHITA	AMBIKA	PALLAVI	54 /IDYASHREI	55 LAKSHMI	ROOPA	POOJA	TULSIBAI	SANGEETA	PUSHPA	ASHWINI	KAVERI	63 Siddamma	Bhagirathi	Kavitha
32 ]/	33 S	34	30 H	36	37 H,	38 28	39	40 \A	41	42 (4	43	\$	45	46 34	47	48 /	49 K	5	51 h	52	8	54 /	53	22	22	8	59 S	99	61 /	62	63 S	64 B	33

# **MASTER CHART – LEVOBUPIVACAINE GROUP**

			APGAR	AT 5 MIN	10	6	6	6	6	6	6	6	6	6	6	6	6	~	~	~	2	~	6	6	6	6	6	6	∞	6	6	6	6	6
		APGAR	AT1 A	MIN AT	2					~	~	6	~	~	~	2	~	2	7	7	9	2	~	~	~	~	~	7	2	~	~	~	~	~~
		A	SHIVERIN	9	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT
			E	S																														
			ç	ITCHING	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	VT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT ABSENT	IT PRESENT	IT ABSENT	IT ABSENT	IT ABSENT					
		-	N HEADAC	罜	- ABSENT	ABSENT	ABSENT	- ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	- ABSENT	T ABSENT	ABSENT	ABSENT	T ABSENT	ABSENT	ABSENT	T ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT
		NAUSEA	VOMITIN	9	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT
			BRADYC	ARDIA	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT
			HYPOTE	NOISN	ABSENT	PRESENT	PRESENT	ABSENT	PRESENT	PRESENT PRESENT	ABSENT	PRESENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	PRESENT	ABSENT	PRESENT PRESENT	ABSENT PRESENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT
			HOH	BB	89	61	09	8	82	59	22	62	92	75	16	8	69	2	81	89	89	8	82	82	<u>7</u> 6	42	<u>1</u>	92	67	22	82	82	33	6
		亨	~	먨	126	127	8	<u>1</u>	133	121	138	106	116	140	135	112	8	118	120	<u>11</u>	118	141	122	123	116	88	152	127	120	134	126	120	53	150
		45	MIM	뤔	2	38	99	82	72	88	88	8	82	33	88	76	82	61	76	8	72	81	76	72	82	\$	8	72	33	35	62	2	\$	92
		\$	NIM	먨	130	120	<u>8</u>	<b>8</b>	51	120	126	107	120	150	131	<u>11</u>	118	107	112	102	120	135	120	51	120	97	150	122	118	114	106	<u>1</u>	145	153
		8	MM	曾	35	2	2	2	2	2	88	22	2	74	8	72	82	62	62	99	29	8	72	2	2	\$	88	2	99	88	56	53	96	91
		8	MIN	ß	8	<u></u>	128	136	11	128	128	92	3	<u>11</u>	120	ġ	120	110	ŝ	106	118	134	118	116	3	ä	<u>11</u>	120	51	126	92	<u>11</u>	151	151
		20	MIN	留	62	2	76	92	67	86	62	62	53	22	67	8	67	63	2	88	8	8	8	4	53	8	63	53	61	62	62	56	74	8
		2	NIM	SB	3	121	122	137	8	136	132	102	112	134	103	107	<u></u>	5 <u>1</u>	3	<u>6</u>	116	12	114	8	112	≘	Ħ	105	120	127	102	120	<del>1</del>	150
		5	NIM	B	99	69	2	8	88	0 <u>1</u>	4	62	53		99	82	66	1 72	22	88	33	22	69	2	53	2	59	99	3	92	62	33	≈ ≠	4
		5	NIM	9 SB	8	123	3	126	11 11	150	124	85	Ξ	133	106	110	112	111	<u>8</u>	102	118	136	<u>11</u>	116	∃	112	105	115	118	126	8	Ξ	134	129
		9	N MIN	P DBP	8 72	6 63	65	20	7 63	54	6 64	09 0	09	9 64	0 64	1 78	7 50	9 61	8 61	09 0	02	4 82	2 68	8	09	3 76	4 59	55	3 75	98	8	09	9	1 66
		5 10	MIN MIN	DBP SBP	68 118	59 116	62 100	80 120	64 117	71 96	72 116	60 100	58 100	60 109	70 100	78 111	69 107	72 109	68 108	62 100	72 110	70 134	60 102	63 118	58 100	73 123	55 104	60 98	75 123	82 130	60 109	58 100	60 109	64 131
		5	MIN	SBP D	11	8	8	128	121	106	126	8	101	110	7 701	101	126 6	115 7	112	96	112 7	126	8	117	101	124	101	35	126	131	01	101	8	127 6
		4	MIN	B	R	35	38	8	33	99	2	09	1	5	7	5	3	F	8	33	R	2	62	3	R	56	33	62	2	23	9	R	2	22
		4	M	B	5	Ξ	101	126	125	24	130	91	114	118	102	103	122	122	113	33	110	128	33	121	117	10	105	112	123	133	8	117	118	130
		ŝ	NW	윰	R	25	99	R	8	99	22	46	22	61	8	2	2	22	89	99	53	88	8	83	1	99	8	09	2		09	7	61	99
		ŝ	M	윩	8	8	<u>8</u>	120	119	110	118	88	115	114	102	8	120	113	113	8	102	132	ജ	125	114	容	101	110	126	Ξ	91	114	115	121
		2	NIM	B	99	5	99	82	99	1 82	2	22	2	63	59	73	2	88	5	8	62	2	99	88	2	99	2	5	72	2	46	12	83	52
		2	N MIN	p SB	8	8	6	128	6	124	8	6	120	107	109	110	114	6	128	130	101	131	6	ett (	115	4	112	134	133	ä	88	5 <u>1</u>	<u>(</u>	123
		-	N	B	8	8	2	8	2	57	4	55	8	69	82	2	6	53	8	8	28	8	2	99	2	2	83	4	22	89	53	2	69	67
			1 MIN	ß	120	2	8	8	3	102	5	111	140	11	<u>6</u>	110	114	97	128	130	9	5	<u>10</u>	8	123	120	108	134	133	걸	8	123	11	131
AL	B00 BL0	8	PRES	SUR	2	8	8	6	29	8	2	2	6	8	6	2	2	8	2	6	8	8	2	2	6	8	6	2	8	64	2	8	8	8
AL	8 8	•	PRES	SURE	8	5	8	8	116	130	120	120	120	130	11	110	120	<u>11</u>	5	<u>1</u>	120	53	11	5	130	120	130 130	130	120	8	5	3	120	120
ATI0	REAC NOF	H ANA	GES	MU A(HO	135	55	120	120	53	210	180	180	210	210	240	180	230	220	210	180	150	81	150	195	81	20	150	160	12	81	180	212	22	185
2	REAC	Ŧ	MOT MAXI GESI	M		7	4	1.3	2	2	~	ŝ	2	4			2	2	7	2	1.2	1.3	~	2	2	ŝ	4		ŝ	~	ŝ	7	4	2
SNO	ш	ъ	MOT	g	0.6		m	0.8		1.3	2	ŝ	0.6	2		0.3	13			0.6					1.2		m	0.8	2	2	7	0.6	7	0.8
DURA	S TION	ъ	SENSO	A RV	180	81	120	150	81	165	180	180	180	180	180	180	210	120	240	180	150	180	135	180	180	210	130	150	150	210	185	162	150	190
ы	REGRES	SION	ъ –	DERMA	160	8	150	120	8	180	150	120	120	81	81	150	8	120	8	120	<u>11</u>	135	120	81	120	210	120	135	120	175	151	<u>1</u>	160	61
2	REAC	Ŧ	14 M	NUTE	2.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	•	0	0	ŝ	0	0	0	0	0	0	0	-
2	SENSO REACH REAC	T10(MI	NUTES	_	2	80	0.8		2.3		ŝ	2.3		4	0.8	0.8		0.8					2	2.3	13	13	m		2	14	2.3		m	
ъ	SENSO	R	BLOCK	: IN YE (MINU	1.3				2		2	2	0.8	ŝ	0.5	0.3	0.8	0.5	0.8	0.8	0.5	0.5	0.8	2		0.8	2	0.6		0.8	2	0.8	2	0.6
					32	26	27	e 35	26	e 22	25	a 22	30	35	22	i 28	61	22	25	a 21	41	28	26	26	e 22	24	a 36	21	ai 26	25	24	i 33	24	26
				NAME	sunita	veda	Gurubai	Jayashree	Jyoti	6 Shagyashrei	sujata	8 shameena	Nikita	Kalavati	Lalitha	Gurudevi	Roopali	Savitri	Nivedita	16 Siddamma	Vijaya	Renuka	Jamuna	Pooja	21 Rajashree	Ashwini	Basamma	Vimala	Hajaratbai	Anitha	Lalitha	Tejaswini	Lakshmi	Prema
	S	N.	M	BER		2	m	4	S	9	~	~	6	9	Ħ	12	8	14	5	16	17	8	٤î	8	21	22	23	24	52	26	27	8	53	8

6	6	6	~	6	6	6	6	6	6	~	6	6	6	6	6	6	6	6	6	~	~	6	6	~	~	~	6	6	6	6	~	6	6	6
~~~	~	~	7		~			~		7				~		~	~	~	~	7	7		2	7	2	7	~		~	~	2	~		~
ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	PRESENT	PRESENT	ABSENT	PRESENT	ABSENT	PRESENT	ABSENT	PRESENT	ABSENT	ABSENT	ABSENT
ABSENT	ABSENT AI	PRESENT PR	ABSENT AI	ABSENT AI	ABSENT AI	ABSENT AI	ABSENT AI	ABSENT AI	ABSENT AI	ABSENT AI	ABSENT AI	ABSENT	ABSENT	ABSENT	ABSENT AI	ABSENT AI	ABSENT AI	ABSENT PR	ABSENT	ABSENT	PRESENT PR	ABSENT AI	ABSENT	ABSENT PR	ABSENT PR	ABSENT AI	ABSENT PR	ABSENT AI	ABSENT PR	ABSENT AI	ABSENT PR	ABSENT AI	ABSENT AI	ABSENT AI
INT ABSENT	NT ABSENT	NT PRESENT	INT ABSENT	NT ABSENT	NT ABSENT	INT ABSENT	INT ABSENT	NT ABSENT	NT ABSENT	NT ABSENT	NT ABSENT	NT ABSENT	INT ABSENT	NT ABSENT	NT PRESENT	NT ABSENT	NT ABSENT	NT ABSENT	NT ABSENT	NT ABSENT	INT ABSENT	NT ABSENT	NT ABSENT	NT ABSENT	NT PRESENT	NT ABSENT	NT ABSENT	INT PRESENT	NT ABSENT	NT PRESENT	NT ABSENT	NT ABSENT	NT ABSENT	NT ABSENT
VT PRESENT	VT ABSENT	VT ABSENT	VT PRESENT	NT ABSENT	NT ABSENT	VT PRESENT	VT PRESENT	VT ABSENT	NT ABSENT	VT ABSENT	NT ABSENT	VT ABSENT	VT PRESENT	VT ABSENT	VT PRESENT	VT ABSENT	VT ABSENT	VT ABSENT	VT ABSENT	VT ABSENT	VT PRESENT	VT ABSENT	VT ABSENT	VT ABSENT	VT ABSENT	VT ABSENT	VT ABSENT	NT PRESENT	VT ABSENT	VT ABSENT	VT ABSENT	VT ABSENT	VT ABSENT	VT ABSENT
T ABSENT	T ABSENT	T ABSENT	T ABSENT	T PRESENT	IT PRESENT	T ABSENT	T ABSENT	IT ABSENT	T PRESENT	T ABSENT	PRESENT PRESENT	IT ABSENT	T ABSENT	IT ABSENT	T ABSENT	T ABSENT	IT ABSENT	PRESENT ABSENT	ABSENT ABSENT	PRESENT ABSENT	T ABSENT	T ABSENT	T ABSENT	T ABSENT	IT ABSENT	T ABSENT	T ABSENT	PRESENT PRESENT	T ABSENT	T ABSENT	T ABSENT	T ABSENT	T ABSENT	T ABSENT
ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	<b>PRESENT</b>	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	PRESEN	PRESENT	ABSENT	PRESENT	ABSENT	ABSENT	PRESENT	PRESEN	ABSEN	PRESEN	ABSENT	ABSENT	ABSENT	ABSENT	PRESENT	ABSENT	ABSENT	PRESEN	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT	ABSENT
82	컮	12	72	102	5	82	62	103	82	65	92	65	2	8	22	99	62	8	82	8	92	8	۴	8	2	2	2	8	8	99	17	8	۴	8
126	138	119	122	147	120	127	141	143	130	107	120	106	140	128	126	118	109	130	118	130	118	112	128	123	112	121	124	120	125	115	5 <u>1</u>	128	120	117
8	2 82	82	8	2 92	8	69	2 75	91	2	28	82	59	8	22	3 76	33	89	2	1 78	2 80	5 76	38	8	53	33	3 72	1 %	2	89	64	35	92	8	8
122	132	130	120	142	120	115	122	1 150	136	106	120	103	138	120	128	113	120	120	121	122	126	118	132	109	108	118	121	102	110	109	113	120	122	120
104 65	136 81	1 76	108 72	140 93	117 53	116 68	137 77	140 101	128 78	1 55	118 72	107 56	141 84	122 82	126 78	118 60	109 71	118 82	130 81	118 72	125 79	1000	130 96	106 50	115 64	89 81	120 80	109 62	118 72	115 72	118 85	110 80	114 72	120 86
64 1(	5	75 131	80 1(	93 1/	50 11	11	83	91 14	86 11	41 111	68 11	55 1(	86 1/	86 11	82 11	11	65 1(	7	78 13	68 11	7	78 121	91 19	79 10	62 11	63 11	82 11	60 1(	60 11	66 11	11	74 11	5	1 11
107	140	123 7	110	146 9	123	124 7	140	131 9	124 8	76 4	114 6	66	138	8 611	128	110	105	126 7	122 7	611	120	118 7	128	127	601	116	120	8	108	106	110	123	118	116 7
64 1	52 1	71	63 1	3	53 1	74 1	88	90	33	51	69 1	51	90	84	76 1	76 1	66 1	90	82 1	70 1	57 1	70	73	68	59 1	60 1	81 1	5	68 1	55 1	1	71	68	7 1
112	611	124	103	135	117	11	143	135	129	87	11	8	140	121	126	128	60	110	118	11	116	128	120	116	66	105	60	8	110	8	121	121	9	114
53	46	\$	5	86	21	2	8	8	53	61	38	25	8	22	8	. 92	27	8	23	62	33	[9	88	22	53	33	2	\$	5	7	8	22	22	22
13	115	134	102	141	131	114	149	149	Ħ	8	102	85	130	5	126	61	8	132	120	120	109	126	92	124	헐	120	118	8	<u>10</u>	109	120	12	120	122
62	64	87	51	92	2	72	8	R	67		99	51	8	09	8	92	1	8	51	63	55	67	8	62	57	R	23	\$	61	82	2		2	61
114	126	132	92	128	109	126	149	115	122	11	8	9	126	96	125	122	115	126	Ξ	124	136	135	96	101	8	5	107	69	114	125	112	123	Ξ	10
1 51	9 61	33	4 76	8	5 50	0 74	90	2 95	4 70	7 52	2 62	54	3 86	09	3 73	8 66	4 69	0 90	3 65	43	2 36	6 72	6 71	8 76	5 42	45	6 67	946	8 64	1 81	2 68	8	2 66	0 83
73 111	74 139	84 133	56 114	87 128	61 125	70 110	88 139	83 132	69 124	59 107	58 92	54 99	80 123	60 100	60 123	70 108	63 104	70 120	53 113	52 90	32 112	74 136	63 126	58 118	57 86	52 90	64 106	57 80	68 118	82 131	60 102	90 128	68 112	72 140
114	135	146 8	8	134 8	134 6	120	143 8	111	136 6	107	3, 3,	103	120	112 6	01	118	97 (	110	110	103	8	106	120	112	96	103	104	8	118 6	128	001	133	116	113
8	47	8	33	53	53	2	22	12	69	8	99	62	53	2	99	6	88	5	8	2	<del>6</del>	69	88	\$	62	2	6	62	2	24	R	83	9	8
13	116	133	8	134	120	110	131	126	119	108	8	13	125	110	11	108	101	8	118	112	6	123	Ħ	8	Ħ	112	103	111	120	140	112	134	8	132
69	8	22	20	88	59	<u>7</u> 6	8	8	72	53	2	61	8	2	2	88	62	2	81	110	8	87	89	82	09	110	2	09	82	92	8	2	2	8
129	120	135	120	125	130	135	139	132	114	Ħ	100	106	130	9	120	106	<b>10</b>	110	Ξ	150	116	135	9	120	115	150	120	115	130	147	9	130	<u>11</u>	E
2	8	2	8	8	8	8	8	22	8	8	25	2	8	R	8	2	99	8	8	<u>10</u>	8	8	R	8	8	8	2	R	8	8	8	⊗	8	82
120	120	110	120	130	110	120	130	120	130	130	121	120	114	110	120	110	102	120	120	160	120	120	110	130	51	140	110	120	120	140	120	120	130	127
8	180	180	17	140	152	210	180	180 180	180	180	17	180	18	15	150	120	180 180	152	120	180	180	185	45	8	225	172	182	180	135	120	120	120	120	120
S	ŝ	ŝ	~	ŝ	2	4	ŝ	ŝ	2	4	ŝ	2	ŝ	4	ŝ	2	ŝ	1.5	ŝ	ŝ	2	ŝ	9	m	S	ŝ	ŝ	4	ŝ	2	4	S	m	4
2			2	2	-	2	2	2		2			2	2.3	2		2		2		2	2	÷	2	2					-		2	2	2
178	<sup>180</sup>	<sup>181</sup>	210	135	150	195	<sup>18</sup>	220	150	160	160	81 81	81 81	160	148	120	180	120	135	81 81	<sup>18</sup>	178	99	8 <u>1</u>	240	186	186	210	125	120	130	145	160	135
152	1 <u>9</u> 0	152	17	120	140	180 180	165	210	5	145	120	15	17	140	128	120	210	136	120	165	220	225	99	135	230	142	1 <u>9</u> 0	230	120	110 110	120	120	135	150
0	0	•	•	•	•	4	•	m	•	•	•	•	•	•	•	•	4	•	•	•	4	•	•	•	S	•	0	5	•	0	•	•	•	•
S	m	2.3	2		2	ŝ	m	2	2	4	2		m	m	m	2	ŝ	2.5	m	m	ŝ	ŝ	9	2	3.5	2	m	ŝ	ŝ	2	m	m	5	m
3	2	2		0.8	0.8		2		0.8	2	0.8	0.8		2	2	2	2	2	2	2	2.3	ŝ	S	-	ŝ	1.5	ŝ	2	2	1.15	2	1.2	ŝ	
i 23	3 24	24	la 28	a 27	n 28	28	22	19	27	32	n 34	28	3 25	e 19	a 22	31	a 26	a 37	a 23	a 22	20	26	31	2	24	25	i 21	ai 29	a 23	32	24	i 24	61	33
31 Saraswati	32 Yallawwa	33 Priyanka	34 Mahananda	35 Nagamma	36 hankramm	37 Shanta	38 Chaitra	39 Nassin	40 Suvarna	41 Arati	42 ijayalakshn	43 Rohini	44 Mabeena	45 Shagyashre	46 Danamma	47 Savitri	48 Nagamma	49 Nagamma	50 Chandrika	51 Mallamma	52 Ranjita	53 Pooja	54 Priyanka	55 Arati	56 Shabana	57 Jyoti	58 Tejaswini	59 Lakshmibai	60 Sushmitha	61 Renuka	62 Pushpa	63 Deepavali	64 Sunita	65 Sangamitra